FULL PAPERS

DOI: 10.1002/adsc.201100173

Diastereoselective Nucleophilic Addition to Aldehydes with Polar α - and α , β -Substituents

Tessie Borg,^a Jakob Danielsson,^a Maziar Mohiti,^a Per Restorp,^a and Peter Somfai^{a,b,*}

^a KTH Chemical Science and Engineering, Organic Chemistry, Royal Institute of Technology, S-10044 Stockholm, Sweden Fax: (+46)-8-791-2333; e-mail: somfai@kth.se

^b Institute of Technology, University of Tartu, Nooruse 1, 504 41 Tartu, Estonia

Received: March 11, 2011; Revised: May 2, 2011; Published online: August 10, 2011

Supporting information for this article is available on the WWW under http://dx.doi.org/10.1002/adcs.201100173.

Abstract: The stereoselectivities obtained in Lewis acid-promoted Mukaiyama aldol additions and Sakurai allylations of mono-, and *syn*- and *anti*-disubstituted aldehydes possessing various polar α - and β -substituents under non-chelating conditions are presented. The stereochemical outcome in the nucleophilic addition to α -substituted aldehydes containing an α -benzyloxy, α -fluoro or α -sulfonamide substituent are accurately predicted by current stereoinduction models.

Introduction

Nucleophilic addition to chiral carbonyl compounds is an important tool for stereoselective C-C bond formation,^[1] and the aldol reaction is an integral part of the arsenal of reactions for the total synthesis of natural products.^[2] In these reactions the addition to the diastereotopic π -faces of a C=O moiety give rise to stereoisomeric products. Thus an integral aspect of these reactions is the ability to predict and control the stereochemical outcome, which is of great importance for the design and synthesis of complex molecules. Consequently, much work has been expended on developing models that accurately predict the π -facial selectivities for this type of reaction.^[3] For additions to a-substituted aldehydes under non-chelation controlled conditions the Felkin-Anh model, in which torsional strain and hyperconjugation are important controlling elements and govern the conformation of the transition state, has been used with great success.^[4] Application of these criteria to aldehydes having an α -heteroatom substituent results in structure A (Scheme 1) having a staggered conformation where the best vicinal acceptor is oriented antiperiplanar to the forming σ -bond. It can be seen that the In contrast, the selectivitites obtained from addition of sterically demanding nucleophiles to α -chloro-substituted aldehydes cannot be rationalized by the same models and an alternative is discussed. The stereochemichal outcome in the additions to α , β -disubstituted aldehydes is more complex and cannot be predicted using current models.

Keywords: aldol reaction; allylation; diastereoselectivity; induction model

polar Felkin–Anh (PFA) model predicts the formation of the *anti* product and this is in accord with experimental observations.^[5]



polar 1,3-asymmetric induction

Scheme 1. The polar Felkin–Anh (A) and Cornforth–Evans (B) models for the addition to α -heteroatom substituted aldehydes, and the polar 1,3-asymmetric induction model (C).

2022

WILEY CONLINE LIBRARY

Recently the validity of the PFA model was questioned by Evans and co-workers who showed that the stereochemical outcome in the addition of E and Zboron enolates to α -alkoxy aldehydes was best rationalized by the modified Cornforth model (B) (Cornforth-Evans).^[6,7] Structure **B** is based on the assumption that, in addition to having a staggered conformation, minimization of dipole interactions is an important transition state control element. Hence, the C-X bond in **B** is almost antiparallel to the carbonyl group. A recent computational study supports the importance of the Cornforth-Evans model in the addition of enol boranes to α -heteroatom-substituted aldehydes having electronegative substituents (X=F,OMe, Cl), while those having less electronegative substituents ($X = NMe_2$, SMe, PMe₂) favor the PFA reaction manifold.^[8]

In contrast, no general models have been advanced for the prediction of the stereochemical outcome in nucleophilic additions to β -substituted aldehydes in the absence of chelation. However, Evans has proposed that for the particular case when the β -substituent is a polar heteroatom moiety (OR, Cl) structure **C**, in which steric and electrostatic effects are minimized, accounts for the observed *anti* selectivity in the BF₃·OEt₂-mediated addition of enolsilanes to these substrates.^[9]

The considerably more complex task of rationalizing the stereochemical outcome in the addition of nucleophiles to α,β -disubstituted aldehydes has been addressed by the Evans group for α -alkyl- β -alkoxy substrates. Superficially, it can be expected that the relative stereochemistry of the major product can be predicted by analyzing the individual directing effects of the α - and β -stereocenters, respectively. In this scenario one stereoisomer of the aldehyde will have a matched combination of the α - and β -stereocenters, which will mutually reinforce the formation of a particular stereoisomeric product, while the other combination will be mismatched. Indeed, Mukaiyama aldol additions to anti- α -methyl- β -alkoxy aldehydes, where both stereodirecting elements promote addition to the same diastereotopic C=O π -face, afforded the products in high selectivity, and transition state (TS) conformation **D** was suggested (Scheme 2).^[9b] As can be seen in structure **D**, both the α - (Felkin–Anh) and β stereocenters (polar 1,3-asymmetric induction model) are acting in concert which favors addition to the C= O Re face. As expected, addition to the corresponding mismatched syn aldehyde proceeded with varying diastereoselectivity. However, in a continuation of this investigation the addition of silvl enol ethers to α,β bisalkoxy aldehydes was also studied.^[10] Based on analysis of the individual stereodirecting contributions from both alkoxy substituents it was predicted that the syn- α , β -bisalkoxy diastereomer should be matched, and that nucleophilic addition to this alde-



Scheme 2. The merged FA-polar 1,3-asymmetric induction model (**D**) and the Cornforth–Evans transition state structures for addition to an *anti*- and *syn*- α , β -bisalkoxy aldehyde (**E** and **F**).

hyde should proceed with high selectivity. Experimentally, however, it was found that the Mukaiyama aldol reactions with anti- α , β -bisalkoxy aldehydes in most cases exhibited good diastereoselectivities, while the corresponding syn isomer displayed lower selectivities. To rationalize the stereochemical outcome both PFA and Cornforth-Evans transition states conformations were analyzed, and by considering the inherent and the developing syn-pentane interactions,^[1d,11] it was concluded that the Cornforth-Evans model most accurately predicted the observed stereochemical trends. Thus, for the BF₃·OEt₂-mediated addition of silyl enol ethers to anti-α,β-bisalkoxy aldehydes transition state structure E was proposed, while the syn isomer should react through transition state F, which suffers from an unfavorable $R \leftrightarrow H$ interaction. It is evident from these studies that prediction of the stereochemical outcome in the nucleophilic addition to $\alpha,\beta\text{-disubstituted}$ aldehydes is far from trivial and cannot be addressed by simple additive analysis of the participating stereocontrolling elements.

As parts of an ongoing investigation we have previosly described a diastereoselective aldol addition α amino- β -silyloxy aldehydes and an unexpected *syn* selectivity in the Mukaiyama aldol addition to α -chlorosubstituted aldehydes.^[12,13] Herein, we report our full investigation of the nucleophilic addition to α - and α , β -polar substituted aldehydes, including chloro-, fluoro-, alkoxy- and amino-substituted aldehydes.

Results and Discussion

α-Substituted Aldehydes

The initial focus of this study was directed towards the investigation of the facial bias exerted by a polar a-substituent in the Mukaiyama aldol addition. a-Substituted aldehydes **1–5**,^[14] having varying electronic and steric properties were selected and subjected to the Mukaiyama aldol addition and the results are summarized in Table 1. α -Alkoxy (entries 7–9)^[10] and α -fluoro aldehydes (entries 10–12) gave generally poor anti selectivity, the trend being that larger nucleophiles gave lower dr. For α -chloro aldehydes (entries 1-6) a similar but more pronounced trend was observed. Addition of the hindered pinacolone enol silane (6a) to α -chloro aldehydes 1 and 2 gave the syn isomer as the major product in good selectivities (entries 1 and 4), which is unanticipated and cannot be predicted by the PFA or the Cornforth-Evans models. A completely opposite trend was observed for the α -sulfonamide 5 (entries 13–15), where an increase in size of the nucleophile led to an enhanced amount of the anti isomer, which is expected on the basis of the PFA model.^[3a]

In order to begin to decipher the observed results an examination of the operative transition states was needed. The validity of the Cornforth–Evans model for additions to α -chloro-, α -alkoxy- and α -fluoro-substituted aldehydes was supported in a recent theoretical investigation of enol borane additions to α -heterosubstituted aldehydes,^[8] and for the latter two substrates this has been verified experimentally.^[6a,15] It was shown that α -substituted aldehydes reacting via the Cornforth-Evans manifold confer a higher diastereoselectivity with boron Z(O)-enolates than with the corresponding E(O)-enolates due to a destabilizing syn-pentane interaction in the E(O)-enolate TS. The opposite trend was observed for substrates reacting via the PFA TS. In a similar vein α -chloro aldehyde 1 was subjected to boron enolates 22 and 23 (Scheme 3).^[12] Addition of E(O)-enolate 22^[16] to aldehyde 1 furnished adduct 24b in modest yield and selectivity, while the use of Z(O)-enolate 23^[16] afforded 25b in excellent yield and selectivity which indicates that also 1 prefers to react through a Cornforth-Evans TS in boron-mediated aldol reactions.

Given these results it is then not clear why α chloro-, α -alkoxy- and α -fluoro-substituted aldehydes react with poor Cornforth–Evans, or even anti-Cornforth–Evans, selectivity in the Mukaiyama aldol reaction (Table 1, entries 1–12). It is generally accepted that the reaction proceeds through an open TS,^[6a,17] having either *antiperiplanar* or *synclinal* TS conformations, although exceptions are known.^[18] To rationalize the stereochemical outcome in the Mukaiyama

			$H \xrightarrow{\text{OTMS}} \frac{\text{BF}_3 \cdot \text{OEt}_2}{\text{CH}_2 \text{CI}_2}$		H O R' +		
Entry	Aldehyde	1 - 5 6a X	R R	7 – 2 [°] 6	1a (syn) R'	7 – 21b (anti) Products ^[b] (Ratio)	Yield ^[c] [%]
1	1	Cl	<i>i</i> -Pr	a	<i>t</i> -Bu	7a:7b (84:16)	99
3	1	Cl	<i>i</i> -Pr	c	<i>l</i> -Pr Me	9a:9b (40:60)	92 94
4	2	Cl	CH_2Ph	a	<i>t</i> -Bu	10a:10b (78:22)	99
5	2	Cl	CH_2Ph	b	<i>i-</i> Pr	11a:11b (29:71)	97
6	2	Cl	CH_2Ph	с	Me	12a:12b (40:60)	94
7 ^[d]	3	OTBS	<i>i</i> -Pr	а	t-Bu	13a:13b (50:50)	66
8 ^[d]	3	OTBS	<i>i</i> -Pr	b	<i>i-</i> Pr	14a:14b (25:75)	69
9 ^[d]	3	OTBS	<i>i</i> -Pr	с	Me	15a:15b (18:82)	66
10	4	F	CH_2Ph	a	<i>t</i> -Bu	16a:16b (43:57)	43
11	4	F	CH_2Ph	b	<i>i</i> -Pr	17a:17b (27:73)	35
12	4	F	CH_2Ph	с	Me	18a:18b (36:64)	63
13	5	NTsBn	<i>i</i> -Pr	a	<i>t</i> -Bu	19a:19b (>2:98)	85
14	5	NTsBn	<i>i</i> -Pr	b	<i>i-</i> Pr	20a:20b (7:93)	94
15	5	NTsBn	<i>i</i> -Pr	c	Me	21a:21b (22:78)	60

Table 1. Mukaiyama aldol reaction to aldehydes 1-5.^[a]

^[a] *Reaction conditions:* To a solution of the aldehyde (1 equiv.) in CH_2Cl_2 at -60 °C was added $BF_3 \cdot OEt_2$ (3 equiv.) and **6** (2 equiv.) and the mixture was stirred for 18 h.

^[b] Diastereomeric ratio was determined by ¹H NMR spectroscopy of the crude reaction mixture.

^[c] Isolated yield.

^[d] See ref.^[10] for experimental details.



Scheme 3. E(O)- and Z(O)-boron enolate additions to α -chloro aldehyde 1.



Scheme 4. Transition state structures in nucleophilic additions to α -chloro aldehydes 1 and 2.

aldol addition to α -chloro-substituted aldehydes **1** and **2** TS structures **G**–**J** will be considered (Scheme 4). Structures **G** and **H** represent Cornforth–Evans structures in which the enol silane has a *synclinal* or *antiperiplanar* orientation, respectively, whereas structures **I** and **J** are anti-Cornforth–Evans arrangements,^[19,20] in which the diastereotopic C=O face is exposed for attack. Also, in structures **I** and **J** the dihedral angle between the carbonyl group and the α -chloro substituent is relatively small, resulting in a destabilizing dipole repulsion.^[21] In the *antiperiplanar* TS **H** the major steric interaction is between the enol silane R'-substituent and the α -chloro substituent,^[9b,22] while the relevant *synclinal* TSs **G** and **I** are characterized by a destabilizing interaction between the enol silane and the Lewis acid coordinated to the carbonyl oxygen.^[9b,17,23]

To differentiate between the *synclinal* and *antiperiplanar* TSs, aldehyde **1** was reacted with enol silanes **6a** ($\mathbf{R'}$ =*t*-Bu) and **6c** ($\mathbf{R'}$ =Me) in the presence of the sterically demanding Lewis acid trityl tetrafluoroborate (Scheme 5).^[9b,24] By increasing the size of the



Scheme 5. Mukaiyama aldol addition to aldehyde 1 using trityl tetrafluoroborate.

Adv. Synth. Catal. 2011, 353, 2022-2036

© 2011 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim

2025

Lewis acid, the *synclinal* TSs are expected to be destabilized and changing the enol silane R'-substituent from Me (**6c**) to *t*-Bu (**6a**) is expected to further disfavor this reaction pathway. However, when using Ph_3CBF_4 the diastereoselectivity remains unchanged within experimental error (compare with Table 1, entries 1 and 3), suggesting that TS structures **G** and **I** are not relevant in this reaction, and that the *antiperiplanar* arrangements **H** and **J** are operative in the Mukaiyama additions to aldehydes **1** and **2**.

It can then be argued that the BF₃·OEt₂-mediated addition of pinacolone enolsilane 6a to aldehydes 1 and 2 will preferentially proceed through J in order to avoid steric interactions with the α -chloro substituent present in structure **H** (Table 1, Entries 1 and 4). When decreasing the size of the enol silane R' moiety the destabilizing steric interactions in H will be attenuated, while the unfavorable dipole interaction in TS structure J remains unchanged, resulting in an increased formation of the anti diastereomer (Table 1, entries 2, 3, 5 and 6). It is also evident that both α -silyloxy aldehyde **3**^[10] and α -fluoro aldehyde **4** follows a similar trend in diastereoselectivity when changing the size of the enol silane (Table 1, entries 7-9 and 10-12, respectively), and it is suggested that similar factors as those outlined in Scheme 4 also dictate the outcome for these substrates.^[25] The higher anti selectivity obtained in the Mukaiyama aldol addition to 3 (X=O) and 4 (X=F) compared to 1 and 2 (X=CI)

could then be rationalized as a manifestation of the increased electronegativity of the α -heteroatom substituent, which should destabilize the TS structure corresponding to **J**, as is observed (Table 1, entries 7–12).

The phenomenon discussed above should be specific for α -heteroatom-substituted aldehydes that preferentially react through Cornforth–Evans TS structures. For aldehydes reacting *via* the PFA manifold, it is well established that smaller nucleophiles generally give lower levels of facial discrimination.^[26] Hence, substrates preferring the PFA conformation are expected to show a reversed dependence of the selectivity on the sterics of the enolsilane.^[27] Indeed, addition of **6a** and **b** to *N*-Ts-*N*-Bn-protected valinal (**5**) proceed with excellent *anti* selectivity, while the addition of **6c** displayed reduced levels of *anti* selectivity (Table 1, entries 13–15, R=t-Bu \rightarrow Me, *syn:anti* > 2:98 \rightarrow 22:78).

α,β-Disubstituted Aldehydes

In the continuation of this study additions to aldehydes having both polar α - and β -substituents were examined, the aim being to unravel any trends in the diastereochemical outcomes. Three sets of aldehydes were selected, all containing a β -alkoxy moiety, while the steric and the electronic properties of the α -substituent were varied: α , β -bisalkoxy aldehydes **28–31**,

Table 2. Mukaiyama aldol reaction to α,β -disubstituted aldehydes **28-37**.^[a]

28 – 37		38a – 47a	38b – 47b
$ \begin{array}{c} PO & O \\ R & \overset{\alpha}{\downarrow} & \overset{\alpha}{\downarrow} \\ X \end{array} H $	OTBS 6a BF ₃ ·OEt ₂ CH ₂ Cl ₂	PO OH O R 5 4 3 t-Bu + 3,4-syn	PO OH O R 5 4 3 X 3,4-anti

Entry	Aldehyde	α,β	Х	Р	R	Products ^[b] (Ratio)	Yield ^[c] [%]
1	28	anti	OBn	Bn	CH ₂ CH ₂ Ph	38a:38b (14:86)	99
2	29	anti	OBn	Bn	$n-C_6H_{13}$	39a:39b (16:84)	93
3	30	syn	OBn	Bn	CH ₂ CH ₂ Ph	40a:40b (49:51)	90
4	31	svn	OBn	Bn	$n-C_6H_{13}$	41a:41b (45:55)	92
5	32	anti	NTsBn	TBS	CH ₂ CH ₂ Ph	42a:42b (> 2:98)	92
6	33	anti	NTsBn	TBS	$c - C_6 H_{11}$	43a:43b (> 2:98)	81
7 ^{d)}	34	syn	NTsBn	TBS	CH ₂ CH ₂ Ph	44a:44b (53:47)	91
8 ^{e)}	35	syn	NTsBn	TBS	$c - C_6 H_{11}$	45a:45b (56:44)	49
9	36	anti	Cl	TBS	CH ₂ CH ₂ Ph	46a:46b (95:5)	99
10	37	syn	Cl	TBS	CH_2CH_2Ph	47a:47b (91:9)	94

^[a] Reaction conditions: To a solution of the aldehyde (1 equiv.) in CH_2Cl_2 at -60 °C was added $BF_3 \cdot OEt_2$ (3 equiv.) and **6a** (2 equiv.) and the mixture was stirred for 18 h.

^[b] Determined by ¹H NMR spectroscopy of the crude reaction mixture.

^[c] Yields are reported for diastereomeric mixtures.

^[d] The reaction time was 40 h.

^[e] The reaction was run at -40 °C.

 α -amino- β -alkoxy derivatives **32–35** and α -chloro- β -silyloxy aldehydes 36 and 37. These substrates were applied in the Mukaiyama aldol addition with silvl enol ether 6a and the Sakurai allylation reaction with allyltrimethylsilane (48), and the results are detailed below.

Nucleophilic additions of TMS-enol ether 6a to anti-aldehydes 28, 29 proceeded in good yields and selectivities to afford the corresponding 3,4-anti isomers (Table 2, entries 1, 2).^[28] In contrast, additions to synaldehydes 30, 31 delivered triols 40 and 41 in equally good yields but with poor diastereoselectivities (entries 3 and 4). Similar observations have been made previously and were rationalized by invoking Cornforth-Evans TS structures (e.g., see E and F, Scheme 2).^[10] In this scenario the lower diastereoselectivities obtained for the syn isomers 30 and 31 were traced to an unfavorable syn-pentane interaction between R and the CHO proton in TS F, which is absent in structure E.

Mukaiyama aldol additions to α -(N-benzyl-N-tosylamino)-β-silyloxy aldehydes 32-35 follow a similar trend.^[13] Thus, addition of **6a** to *anti*-aldehydes **32** and 33 afforded the corresponding 3,4-anti adducts 42b and 43b, respectively, in excellent yields and diastereoselectivities (Table 2, entries 5 and 6) while aldol additions to syn-aldehydes 34 and 35 resulted in lower yields and no appreciable selectivity (entries 7 and 8). Although it would be tempting to speculate that the stereochemical outcome for aldehydes 32-35 can be rationalized by applying similar models as for α,β -bi-

PO

0

salkoxy aldehydes **28–31**,^[10] it is assumed that the former aldehydes react through a PFA manifold and,^[8] consequently, that the Cornforth-Evans TS structures proposed for 28-31 do not apply. Although we can offer no explanation for the stereochemical outcome in additions to aldehydes 32-35 it is noted that these results could not have been predicted by simply analyzing the individual contributions from the α - and β -stereocenters, respectively. This point is further highlighted by the π -facial selectivities obtained in the Mukaiyama aldol reactions with α -chloro- β -silyloxy aldehydes 36 and 37 (entries 9 and 10). Additions to both anti-36 and syn-37 afforded the 3,4-syn products 46a and 47a, respectively, in excellent yield and with high diastereoselectivity. Superficially, it appears as the α -chloro substituent dictates the stereochemical outcome and that the β -substituent only has a minor influence. Once again, this outcome could not have been predicted by applying the conventional induction models. Taken together, the results in Table 2 highlight the increased complexity of predicting the stereochemical outcome in the Mukaiyama aldol addition to α,β -disubstituted aldehydes compared to α -substituted ones.

In order to further investigate the nucleophilic addition to these substrates. Sakurai allylations of aldehydes 28–37 were performed. The π -facial selectivities in these additions are presented in Table 3. In general, the stereochemical trends are in line with those obtained in the Mukaiyama aldol reaction. Allylation of aldehyde 28 and 29 proceeded with similar diastereo-

PO

OH

Table 3. Sakurai allylation reaction to α , β -disubstituted aldehydes **28–37**.^[a]

TMS 48

		$\begin{array}{c} PO \\ R \\ \downarrow \\ X \\ \end{array} H \\ \begin{array}{c} BF_3OEt_2 \\ CH_2Cl_2 \\ \end{array}$		R 5 4 3 + X 3,4-syn 49a - 58a		R 5 4 3 X 3,4-anti 49b – 58b	
Entry	Aldehyde	α,β	Х	Р	R	Products (Ratio) ^[b]	Yield [%] ^[c]
1	28	anti	OBn	Bn	CH ₂ CH ₂ Ph	49a:49b (13:87)	95
2	29	anti	OBn	Bn	$n - C_6 H_{13}$	50a:50b (16:84)	93
3	30	syn	OBn	Bn	CH ₂ CH ₂ Ph	51a:51b (21:79)	83
4	31	syn	OBn	Bn	$n - C_6 H_{13}$	52a:52b (33:67)	87
5	32	anti	NTsBn	TBS	CH ₂ CH ₂ Ph	53a:53b (13:87)	67
6	33	anti	NTsBn	TBS	$c - C_6 H_{11}$		decomp. ^[d]
7	34	syn	NTsBn	TBS	CH ₂ CH ₂ Ph	54a:54b (45:55)	< 5
8	35	syn	NTsBn	TBS	$c - C_6 H_{11}$		decomp. ^[d]
9	36	anti	Cl	TBS	CH ₂ CH ₂ Ph	55a:55b (60:40)	88
10	37	syn	Cl	TBS	CH ₂ CH ₂ Ph	56a:56b (59:41)	94

PO

ОН

[a] *Reaction conditions:* To a solution of the aldehyde (1 equiv.) in CH₂Cl₂ at -60 °C was added BF₃·OEt₂ (3 equiv.) and allyltrimethylsilane (2 equiv.) and the mixture was stirred for 18 h.

[b] Isolated yield.

[c] Determined by ¹H NMR spectroscopy of the crude reaction mixture.

^[d] No allylation, even at elevated temperature, only decomposition of the aldehyde was observed.

Tessie Borg et al.

selectivity as in the addition of pinacolone enol silane (6a) to these substrates. In contrast, the additions to the corresponding *syn*-aldehydes **30** and **31** proceeded with higher *anti* selectivities.^[29] Sakurai allylation of *anti*- α -amino- β -silyloxy aldehyde **32** displayed reduced selectivity compared with the Mukaiyama aldol addition, which would be expected from a PFA-controlled reaction.^[26] All attempts to allylate aldehydes **33** and **35**, even at elevated temperatures, were unsuccessful and gave only decomposition products. The diminished diastereoselectivity in the allylations of aldehyde **36** and **37** compared with the Mukaiyama aldol additions (Table 2, entries 11 and 12) should be noted and indicates that the size of the nucleophile influences the selectivity in the addition to these substrates.

Conclusions

In conclusion, it has been shown that the stereochemical outcome in the Mukaiyama aldol addition to α chloro-substituted aldehydes is sensitive to the size of the silyl enol ether and it is proposed that small nucleophiles preferentially react through Cornforth-Evans TS structures, while sterically more hindered enol silanes preferentially react through anti-Cornforth-Evans TS. A similar relationship between the size of the nucleophile and the stereochemical outcome is also observed for a-alkoxy- and a-fluoro-substituted aldehydes, and it is proposed that similar factors govern the diastereofacial selectivity with this class of substrates. It has also been shown that α -sulfonamide-substituted aldehydes, which preferentially react through a PFA manifold, follow the opposite trend, i.e., an increase in the size of the nucleophile gives higher diastereoselectivity in favor of the anti diastereomer. It has also been shown that the stereochemical outcome in the Mukaiyama aldol addition and Sakurai allylation of α , β -bisheteroatom-substituted aldehydes cannot be predicted using current models for rationalizing stereoinduction.

Experimental Section

¹H and ¹³C NMR spectra were recorded in CDCl₃ using the residual peak of CHCl₃ (¹H: δ = 7.26; ¹³C δ = 77.0). Only the strongest/structurally most important peaks (cm⁻¹), in the IR spectra, are listed. Analytical TLC plates were visualized with UV light and phosphomolybdic acid/cerium sulfate staining reagent. Air- and moisture-sensitive reactions were carried out in flame-dried, septum-capped flasks under an atmospheric pressure of N₂. All liquid reagents were transferred *via* oven-dried syringes. THF and CH₂Cl₂ were dried using a Glass-contour solvent dispersion system.

Mukaiyama Aldol Reaction: Aldehydes 1, 2, 4, 5, 28–37

The experimental procedure for Mukaiyama aldol reaction of aldehyde 1 with enol ether **6a** is representative for all aldehydes 1, 2, 6, 7, 9.

(5*S**,6*S**/5*R**,6*S**)-6-Chloro-5-hydroxy-2,2,7-trimethyloctan-3-one (7a, 7b)

To a stirred solution of **1** (19 mg, 156 µmol) in CH_2Cl_2 (1 mL) was added BF₃·OEt₂ (60 µL, 468 µmol) at -60 °C. After 5 min. was added **6a** (69 µL, 312 µmol) and the resultant solution was stirred at -60 °C for 18 h. The reaction was quenched by addition of H₂O (5 mL) and allowed to reach room temperature. The aqueous phase was extracted with CH_2Cl_2 (3×7 mL), dried (MgSO₄) and concentrated under reduced pressure to afford **7a** and **7b** as a colorless oil; yield: 34 mg (99%), *dr* 86:14 (*syn:anti*). The diastereomers were separated by flash chromatography (pentane:E-tOAc 12:1).

Major isomer **7a**, white solid mp 40–45 °C. ¹H NMR (CDCl₃, 500 MHz): δ =4.37 (ddd, *J*=7.5, 4.5, 2.9 Hz, 1H), 3.68 (dd, *J*=7.6, 2.9 Hz, 1H), 2.89 (dd, *J*=17.7, 7.7 Hz, 1H), 2.76 (dd, *J*=17.8, 4.6 Hz, 1H), 2.68 (s, 1H), 2.14 (qd, *J*=13.4, 6.7, 6.7, 6.7 Hz, 1H), 1.15 (s, 9H), 1.08 (t, *J*=6.9, 6.9 Hz, 6H); ¹³C NMR (CDCl₃, 125 MHz): δ =215.6, 74.3, 68.0, 44.4, 41.9, 32.4, 26.2, 20.3, 19.9; IR (film): v_{max}=3491, 2962, 1701, 737 cm⁻¹; HR-MS (FAB+): *m/z*=221.1303, calcd. for C₁₁H₂₁ClO₂ (M+H): 221.1308.

Minor isomer **7b**, colorless oil. ¹H NMR (CDCl₃, 500 MHz): $\delta = 4.05$ (dt, J = 8.6, 8.5, 2.4 Hz, 1H), 3.78 (dd, J = 8.9, 3.4 Hz, 1H), 3.72–3.55 (br s, 1H), 3.08 (dd, J = 18.0, 2.4 Hz, 1H), 2.78 (dd, J = 18.0, 8.1 Hz, 1H), 2.41 (m, 1H), 1.18–1.15 (s, 9H), 1.02 (d, J = 6.8 Hz, 3H), 0.97 (d, J = 6.6 Hz, 3H); ¹³C NMR (CDCl₃, 125 MHz): $\delta = 218.3$, 71.3, 69.4, 44.6, 40.0, 29.0, 26.2, 20.7, 15.6; IR (film): $v_{max} = 3479$, 2966, 1689, 725 cm⁻¹; HR-MS (FAB+): m/z = 221.1303, calcd. for C₁₁H₂₁ClO₂ (M+H): 221.1308.

(5*S**,6*S**/5*R**,6*S**)-6-Chloro-5-hydroxy-2,7-dimethyloctan-3-one (8a, 8b)

Prepared from aldehyde **1** and enol silane **6b** as described for **7a** and **7b** to afford **8a** and **8b** as a colorless oil; yield: 112 mg (83%); *dr* 35:65 (*syn:anti*). The diastereomers were separated by flash chromatography (pentane:EtOAc 8:1).

Minor isomer **8a**. ¹H NMR (CDCl₃, 500 MHz): δ =4.37 (td, *J*=7.5, 3.7, 3.7 Hz, 1H), 3.68 (dd, *J*=7.3, 3.1 Hz, 1H), 2.86 (dd, *J*=17.5, 7.9 Hz, 1H), 2.71 (dd, *J*=17.5, 4.4 Hz, 1H), 2.67 (s br, 1H), 2.61 (m, 1H), 2.19–2.08 (m, 1H), 1.11 (d, *J*=7.0 Hz, 6H), 1.07 (dd, *J*=6.5, 5.4 Hz, 6H); ¹³C NMR (CDCl₃, 125 MHz): δ =214.1, 74.4, 68.0, 45.2, 41.5, 32.3, 20.4, 19.7, 17.99, 17.95; IR (film): v_{max}=3479, 2970, 1709, 741 cm⁻¹; HR-MS (FAB+): *m*/*z*=207.1147, calcd. for C₁₀H₁₉ClO₂ (M+H): 207.1146.

Major isomer **8b.** ¹H NMR (CDCl₃, 500 MHz): δ = 4.05 (dt, J = 8.5, 8.5, 2.3 Hz, 1H), 3.74 (dd, J = 8.7, 3.5 Hz, 1H), 3.51 (s br, 1H), 3.01 (dd, J = 17.9, 2.5 Hz, 1H), 2.73 (dd, J = 18.0, 8.2 Hz, 1H), 2.61 (m, 1H), 2.42–2.31 (m, 1H), 1.10 (d, J = 6.9 Hz, 6H), 1.00 (d, J = 6.8 Hz, 3H), 0.94 (d, J = 6.6 Hz, 3H); ¹³C NMR (CDCl₃, 125 MHz): δ = 214.1, 74.4, 68.0, 45.2, 41.5, 32.3, 20.4, 19.7, 17.99, 17.96; IR (film): v_{max} = 3475,

2970, 1704, 733 cm⁻¹; HR-MS (FAB+): m/z = 207.1149, calcd. for C₁₀H₁₉ClO₂ (M+H): 207.1146.

(5*S**,6*S**/5*R**,6*S**)-5-Chloro-4-hydroxy-6-methylheptan-2-one (9a, 9b)

Prepared from aldehyde **1** and enol silane **6c** as described for **7a** and **7b** to afford **9a** and **9b** as a colorless oil; yield: 136 mg (94%); *dr* 40:60 (*syn:anti*). The diastereomers were separated by flash chromatography (pentane:EtOAc 6:1).

Minor isomer **9a**. ¹H NMR (CDCl₃, 500 MHz): δ = 4.36 (m, 1H), 3.67 (dd, *J*=7.1, 3.4 Hz, 1H), 2.85 (dd, *J*=17.3, 8.2 Hz, 1H), 2.67 (dd, *J*=17.3, 4.1 Hz, 1H), 2.62 (s br, 1H), 2.21 (s, 3H), 2.13 (qd, *J*=13.5, 6.7, 6.7, 6.7 Hz, 1H), 1.07 (dd, *J*=6.7, 3.4 Hz, 6H); ¹³C NMR (CDCl₃, 125 MHz): δ = 207.9, 74.3, 68.0, 48.4, 32.2, 30.9, 20.4, 19.5; IR (film): v_{max} = 3456, 2966, 1712, 737 cm⁻¹; HR-MS (FAB+): *m*/*z* = 201.0653, calcd. for C₈H₁₅ClNaO₂ (M+Na): 201.0653.

Major isomer **9b**: ¹H NMR (CDCl₃, 400 MHz): δ =4.10 (dt, J=8.6, 8.6, 2.5 Hz, 1H), 3.75 (dd, J=8.6, 3.7 Hz, 1H), 3.36 (s br, 1H), 3.01 (dd, J=18.0, 2.4 Hz, 1H), 2.72 (dd, J=18.0, 8.5 Hz, 1H), 2.35 (dtd, J=13.4, 6.7, 6.7, 3.7 Hz, 1H), 2.21 (s, 3H), 1.01 (d, J=6.8 Hz, 3H), 0.96 (d, J=6.6 Hz, 3H); ¹³C NMR (CDCl₃, 125 MHz): δ =210.1, 71.3, 68.9, 46.7, 30.9, 29.0, 20.6, 15.8; IR (film): v_{max} =3448, 2966, 1708, 733 cm⁻¹; HR-MS (FAB+): m/z=201.0651, calcd. for C₈H₁₅ClNaO₂ (M+Na): 201.0653.

(5*S**,6*S**/5*R**,6*S**)-6-Chloro-5-hydroxy-2,2-dimethyl-7-phenylheptan-3-one (10a, 10b)

Prepared from aldehyde **2** as described for **7a** and **7b** to afford **10a** and **10b** as a colorless oil; yield: 575 mg (99%); dr 78:22 (*syn:anti*). The diastereomers were separated by flash chromatography (heptane:EtOAc 5:1 \rightarrow 3:1).

Major isomer **10a**. ¹H NMR (CDCl₃, 500 MHz): δ = 7.30 (m, 5H), 4.22 (ddd, *J*=8.3, 3.9, 2.2 Hz, 1H), 4.16 (ddd, *J*= 8.6, 6.6, 2.2 Hz, 1H), 3.32 (dd, *J*=14.0, 6.6 Hz, 1H), 3.12 (dd, *J*=14.0, 8.2 Hz, 1H), 3.03 (s br, 1H), 2.92 (dd, *J*=17.9, 8.3 Hz, 1H), 2.81 (dd, *J*=17.9, 4.0 Hz, 1H), 1.16 (s, 9H); ¹³C NMR (CDCl₃, 125 MHz): δ =216.0, 137.6, 129.3, 128.5, 126.8, 68.2, 66.8, 44.4, 41.0, 40.8, 26.2; IR (film): v_{max}=3479, 2970, 1701, 702 cm⁻¹; HR-MS (FAB+): *m*/*z*=269.1304, calcd. for C₁₅H₂₁ClO₂ (M+H): 269.1303.

Minor isomer **10b.** ¹H NMR (CDCl₃, 500 MHz): δ = 7.37–7.22 (m, 5H), 4.12 (ddd, *J*=8.6, 7.2, 3.9 Hz, 1H), 4.07 (t, *J*=7.5, 7.5 Hz, 1H), 3.69 (s br, 1H), 3.37 (dd, *J*=14.4, 3.8 Hz, 1H), 3.03–2.93 (m, 2H), 2.85 (dd, *J*=18.0, 8.0 Hz, 1H), 1.17 (s, 9H); ¹³C NMR (CDCl₃, 125 MHz): δ =217.5, 137.3, 129.6, 128.3, 126.8, 70.8, 65.5, 44.6, 40.1, 39.2, 26.2; IR (film): v_{max} =2475, 2970, 1701, 702 cm⁻¹; HR-MS (FAB+): *m*/*z* = 269.1305, calcd for C₁₅H₂₁ClO₂ (M+H): 269.1303.

(5*S**,6*S**/5*R**,6*S**)-6-Chloro-5-hydroxy-2-methyl-7phenylheptan-3-one (11a, 11b)

Prepared from aldehyde **2** and enol silane **6b** as described for **7a** and **7b** to afford **11a** and **11b** as a colorless oil; yield: 163 mg (97%); *dr* 29:71 (*syn:anti*). The diastereomers were separated by flash chromatography (heptane:EtOAc 5:1).

Minor isomer **11a**: ¹H NMR (CDCl₃, 500 MHz): δ = 7.36–7.30 (m, 2H), 7.29–7.24 (m, 3H), 4.22 (ddd, *J*=8.5, 3.8, 2.4 Hz, 1H), 4.13 (ddd, *J*=6.7, 8.1, 2.4 Hz, 1H), 3.31 (dd,

 $J=14.0, 6.7 \text{ Hz}, 1 \text{ H}), 3.10 \text{ (dd, } J=14.0, 8.1 \text{ Hz}, 1 \text{ H}), 2.90 \text{ (dd, } J=17.8, 8.5, \text{ Hz}, 1 \text{ H}), 2.75 \text{ (dd, } J=17.8, 3.8 \text{ Hz}, 1 \text{ H}), 2.61 \text{ (hept, } J=6.9 \text{ Hz}, 1 \text{ H}), 1.12 \text{ (d, } J=6.9 \text{ Hz}, 3 \text{ H}), 1.11 \text{ (d, } J=6.9 \text{ Hz}, 3 \text{ H}); {}^{13}\text{C} \text{ NMR} \text{ (CDCl}_3, 125 \text{ MHz}): \delta=214.6, 137.6, 129.3, 128.5, 126.9, 68.1, 66.8, 44.3, 41.5, 40.8, 17.96, 17.95; \text{ IR (film): } v_{\text{max}}=3467, 2970, 1705, 702 \text{ cm}^{-1}; \text{ HR-MS} \text{ (FAB+): } m/z=255.1147, \text{ calcd. for } C_{14}\text{H}_{19}\text{ClO}_2 \text{ (M+H): } 255.1146.$

Major isomer **11b**: ¹H NMR (CDCl₃, 500 MHz): δ = 7.34-7.28 (m, 2H), 7.27-7.22 (m, 3H), 4.12-4.05 (m, 2H), 3.59 (br s, 1H), 3.34 (dd, *J*=14.4, 3.3 Hz, 1H), 2.99-2.91 (m, 2H), 2.82 (dd, *J*=17.8, 7.9 Hz, 1H), 2.62 (hept, *J*=6.9 Hz, 1H), 1.12 (d, *J*=6.9 Hz, 3H), 1.11 (d, *J*=6.9 Hz, 3H).; ¹³C NMR (CDCl₃, 125 MHz): δ =214.6, 137.6, 129.3, 128.5, 126.9, 68.1, 66.8, 44.3, 41.5, 40.8, 17.96, 17.95; IR (film): v_{max} =3479, 2970, 1709, 1466, 1045 cm⁻¹; HR-MS (FAB+): *m*/*z*=255.1145, calcd. for C₁₄H₁₉ClO₂ (M+H): 255.1146.

(5*S**,6*S**/5*R**,6*S**)-6-Chloro-5-hydroxy-2,2-dimethyl-7-phenylheptan-3-one (12a, 12b)

Prepared from aldehyde **2** and enol silane **6c** as described for **7a** and **7b** to afford **12a** and **12b** as a colorless oil; yield: 354 mg (51%); *dr* 66:34 (*syn:anti*). The following ratios were used: aldehyde 2 equiv., BF₃·OEt₂ 2 equiv., enol silane 1 equiv. The diastereomers were separated by preparative HPLC (hexanes 99.5%, 2-propanol 0.5%).

Minor isomer **12a**. ¹H NMR (CDCl₃, 500 MHz): δ = 7.35–7.30 (m, 2H), 7.28–7.24 (m, 3H), 4.24–4.19 (ddd, *J*=8.7, 3.6, 2.3 Hz, 1H), 4.11 (ddd, *J*=8.0, 6.8, 2.3 Hz, 1H), 3.29 (dd, *J*=14.0, 6.8 Hz, 1H), 3.09 (dd, *J*=14.0, 8.0 Hz, 1H), 2.90 (dd, *J*=17.8, 8.7 Hz, 1H), 2.71 (dd, *J*=17.8, 3.6 Hz, 1H), 2.19 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz): δ =208.4, 137.5, 129.3, 128.6, 126.9, 67.9, 66.8, 47.6, 40.8, 30.7; IR (film): v_{max}=3448, 2912, 1712, 702 cm⁻¹; HR-MS (FAB+): *m*/*z*=227.0833, calcd. for C₁₂H₁₅ClO₂ (M+H): 227.0833.

Major isomer **12b.** ¹H NMR (CDCl₃, 500 MHz): δ = 7.35–7.30 (m, 2H), 7.28–7.24 (m, 3H), 4.14–4.08 (m, 2H), 3.42 (br s, 1H), 3.32 (dd, *J*=14.4, 3.3 Hz, 1H), 2.98–2.92 (m, 2H), 2.81 (dd, *J*=17.9, 8.1 Hz, 1H), 2.22 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz): δ = 209.4, 137.2, 129.5, 128.4, 126.9, 70.4, 65.5, 45.9, 40.1, 30.9; IR (film): v_{max} =3440, 2931, 1701, 1408, 698 cm⁻¹; HR-MS (FAB+): *m*/*z*=227.0834, calcd. for C₁₂H₁₅ClO₂ (M+H): 227.0833.

(5*S**,6*S**/5*R**,6*S**)-6-Fluoro-5-hydroxy-2,2-dimethyl-7-phenylheptan-3-one (16a, 16b)

Prepared from aldehyde **4** as described for **7a** and **7b** to afford **16a** and **16b** as a colorless oil; yield: 55.0 mg (43%), dr 43:57 (*syn:anti*).

Minor isomer **16a**. ¹H NMR (CDCl₃, 500 MHz): δ = 7.27-7.16 (m, 5H), 4.51 (dddd, *J*=47.0, 7.9, 5.9, 2.3 Hz, 1H), 4.01 (ddddd, *J*=16.2, 4.8, 3.1, 3.1, 3.0 Hz, 1H), 3.07 (d, *J*= 4.8 Hz, 1H), 3.09–2.95 (m, 2H), 2.81 (dd, *J*=17.9, 9.0 Hz, 1H), 2.66 (dd, *J*=17.9, 3.3 Hz, 1H), 1.08 (s, 9H); ¹³C NMR (125 MHz, CDCl₃): δ =216.6, 136.9 (d, *J*=6.4 Hz), 129.4, 128.6, 126.7, 95.6 (d, *J*=177.1 Hz), 67.8 (d, *J*=20.0 Hz), 39.2 (d, *J*=3.6 Hz), 37.1 (d, *J*=22.2 Hz), 26.3; IR (film): v_{max} = 3437, 2924, 1701, 1369, 1169 cm⁻¹; HR-MS (FAB+): *m*/*z* = 253.1597, calcd. for C₁₅H₂₁FO₂ (M+H): 253.1598. Major isomer **16b.** ¹H NMR (CDCl₃, 500 MHz): δ =7.35–7.22 (m, 5H), 4.56 (dddd, *J*=47.9, 7.5, 7.5, 3.3 Hz, 1H), 4.04–3.97 (m, 1H), 3.55 (d, *J*=4.3 Hz, 1H), 3.15 (ddd, *J*= 32.9, 14.7, 3.3 Hz, 1H), 2.95 (ddd, *J*=23.0, 14.8, 7.9 Hz, 1H), 2.88 (ddd, *J*=18.0, 2.2, 2.2 Hz, 1H), 2.71 (dd, *J*=18.0, 8.6 Hz, 1H), 1.15 (s, 9H); ¹³C NMR (125 MHz, CDCl₃): δ = 217.7, 136.9 (d, *J*=1.6 Hz), 129.6, 128.4, 126.6, 94.9 (d, *J*= 174.0 Hz), 68.8 (d, *J*=24.9 Hz), 44.6, 38.4 (d, *J*=3.6 Hz), 37.7 (d, *J*=20.4 Hz), 26.2; IR (neat): v_{max}=3475, 2966, 1701, 1365, 1061 cm⁻¹; HR-MS (FAB+): *m*/*z*=253.1591, calcd. for C₁₅H₂₁FO₂ (M+H): 253.1598.

(5*S**,6*S**/5*R**,6*S**)-6-Fluoro-5-hydroxy-2-methyl-7phenylheptan-3-one (17a, 17b)

Prepared from aldehyde **4** and enol silane **6b** as described for **7a** and **7b** to afford **17a** and **17b** as a colorless oil; yield: 63.0 mg (35%); *dr* 27:73 (*syn:anti*).

Minor isomer **17a**. ¹H NMR (400 MHz, CDCl₃): δ =7.35–7.22 (m, 5H), 4.57 (dddd, *J*=46.4, 8.0, 5.9, 2.5 Hz, 1H), 4.16–4.04 (m, 1H), 3.13–3.00 (m, 3H), 2.86 (dd, *J*=17.7, 9.0 Hz, 1H), 2.69 (dd, *J*=17.7, 3.4 Hz, 1H), 2.61 (hept, *J*=6.9 Hz, 1H), 1.12 (d, *J*=6.9 Hz, 3H), 1.11 (d, *J*=6.9 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃): δ =215.0, 136.8 (d, *J*=6.3 Hz), 129.4, 128.6, 126.7, 95.6 (d, *J*=177.0 Hz), 67.7 (d, *J*=20.1 Hz), 42.5 (d, *J*=3.5 Hz), 41.6, 37.0 (d, *J*=22.2 Hz), 18.0, 17.9; IR (neat): v_{max}=3341, 1709, 1643 cm⁻¹; HR-MS (FAB+): *m*/*z*=239.1439, calcd. for C₁₄H₁₉FO₂ (M+H): 239.1442.

Major isomer **17b.** ¹H NMR (500 MHz, CDCl₃): δ = 7.26–7.15 (m, 5H), 4.56–4.48 (m, 1H), 3.96 (q, *J*=7.0 Hz, 1H), 3.41 (s, 1H), 3.06 (ddd, *J*=33.1, 14.8, 3.3 Hz, 1H), 2.88 (ddd, *J*=22.9, 14.7, 8.0 Hz, 1H), 2.77 (dt, *J*=17.9, 2.3 Hz, 1H), 2.62 (dd, *J*=17.9, 8.6 Hz, 1H), 2.53 (hept, *J*=7.0 Hz, 1H), 1.04 (d, *J*=2.7 Hz, 3H), 1.03 (d, *J*=2.7 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃): δ =216.0, 136.8 (d, *J*=1.6 Hz), 129.5, 128.4, 126.6, 94.9 (d, *J*=174.2 Hz), 68.6 (d, *J*=24.8 Hz), 41.7 (d, *J*=3.6 Hz), 41.6, 37.6 (d, *J*=20.4 Hz), 17.9, 17.9; IR (neat): v_{max}=3340, 2966, 1709, 1462, 1107 cm⁻¹; HR-MS (FAB+): *m*/*z*=239.1440, calcd. for C₁₄H₁₉FO₂ (M+H): 239.1442.

(5*S**,6*S**/5*R**,6*S**)-5-Fluoro-4-hydroxy-6-phenylhexan-2-one (18a, 18b)

Prepared from aldehyde **4** and enol silane **6c** as described for **7a** and **7b** to afford **18a** and **18b** as a colorless oil; yield: 112 mg (63%); *dr* 36:64 (*syn:anti*).

Minor isomer **18a**. ¹H NMR (500 MHz, CDCl₃): δ =7.22 (m, 5H), 4.56 (dddd , *J*=46.7, 8.0, 5.8, 2.6 Hz, 1H), 4.10 (dddd, *J*=24.6, 9.1, 2.8, 2.8 Hz, 1H), 3.01 (m, 2H), 2.97 (br s, 1H), 2.86 (dd, *J*=17.7, 9.1 Hz, 1H), 2.67 (dd, *J*=17.7, 3.3 Hz, 1H), 2.20 (s, 3H); ¹³C NMR (126 MHz, CDCl₃): δ = 209.6, 136.72 (d, *J*=1.7 Hz), 129.5, 128.5, 126.7, 94.9 (d, *J*=174.2 Hz), 68.4 (d, *J*=24.9 Hz), 45.0 (d, *J*=3.7 Hz), 37.6 (d, *J*=20.5 Hz), 30.9; IR (neat): v_{max}=3371, 1709, 1107 cm⁻¹; HR-MS (FAB+): *m*/*z*=211.1127, calcd. for C₁₂H₁₅FO₂ (M+H): 211.1129.

Major isomer **18b.** ¹H NMR (500 MHz, CDCl₃): δ = 7.34– 7.23 (m, 5H), 4.56 (dddd, *J*=47.8, 8.0, 7.5, 3.3 Hz, 1H), 4.10–4.02 (m, 1H), 3.30 (d, *J*=4.5 Hz, 1H), 3.12 (ddd, *J*= 33.0, 14.8, 3.3 Hz, 1H), 2.95 (ddd, *J*=22.9, 14.7, 8.0 Hz, 1H), 2.85 (unresolved ddd, J=18.0 Hz, 1H), 2.68 (dd, J=18.0, 8.8 Hz, 1H), 2.20 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): $\delta =$ 209.7, 136.71 (d, J=1.7 Hz), 129.5, 128.5, 126.7, 94.9 (d, J=174.2 Hz), 68.4 (d, J=24.9 Hz), 45.0 (d, J=3.6 Hz), 37.6 (d, J=20.4 Hz), 30.9; IR (neat): $v_{max}=3371$, 1709, 1107 cm⁻¹; HR-MS (FAB+): m/z = 211.1127, calcd. for $C_{12}H_{15}FO_2$ (M + H): 211.1129.

(5*R**,6*S**)-6-(*N*-Benzyl-*N*-tosylamino)-5-hydroxy-2,2,7-trimethyloctan-3-one (19b)^[12]

Prepared from aldehyde **5** as described for **7a** and **7b** to afford **19b** as a colorless oil; yield: 90 mg (85%); dr > 2:98 (*syn:anti*).

Major isomer **19b.** ¹H NMR (CDCl₃, 400 MHz): δ = 7.68 (d, J = 8.2 Hz, 2H), 7.46 (d, J = 7.0 Hz, 2H), 7.35–7.21 (m, 5H), 4.61 (d, J = 15.4 Hz, 1H), 4.36 (d, J = 15.4 Hz, 1H), 4.01 (m, 1H), 3.43 (m, 1H), 3.26 (d, J = 2.2 Hz, 1H), 2.53 (m, 2H), 2.42 (s, 3H), 1.91 (m, 1H), 1.04 (s, 9H), 0.74 (d, J = 6.8 Hz, 6H); ¹³C NMR (CDCl₃, 100 MHz): δ = 217.5, 143.2, 138.2, 137.6, 129.6, 129.1, 128.4, 127.7, 127.3, 69.2, 44.2, 41.7, 29.3, 26.3, 22.3, 21.5, 20.2; IR (neat): v_{max} = 3400, 2970, 1690, 1160 cm⁻¹; HR-MS (FAB+): m/z = 446.2359, calcd. for C₂₅H₃₅NO₄S (M+H): 446.2365.

(5R*,6S*)-6-(*N*-Benzyl-*N*-tosylamino)-5-hydroxy-2,7dimethyloctan-3-one (20a, 20b)

Prepared from aldehyde **5** and enol silane **6b** as described for **7a** and **7b** to afford **20a** and **20b** as a colorless oil; yield: 140 mg (94%); *dr* 7:93 (*syn:anti*). The diastereomers were separated by flash chromatography (heptane:EtOAc 6:1).

Major isomer **20b.** ¹H NMR (CDCl₃, 500 MHz): $\delta = 7.69$ (d, J = 8.2 HZ, 2H), 7.48 (d, J = 7.2 Hz, 2H), 7.34–7.24 (m, 5H), 4.63 (d, J = 15.4 Hz, 1H), 4.33 (d, J = 15.4 Hz, 1H), 3.99 (unresolved m, 1H), 3.43 (unresolved m, 1H), 3.27 (br s, J = 2.1 Hz, 1H), 2.55–2.35 (m, 6H), 1.96–1.77 (unresolved m, 1H), 1.03 (d, J = 6.8 Hz, 3H), 1.01 (d, J = 6.9 Hz, 3H), 0.97 (d, J = 6.9 Hz, 3H), 0.73 (d, J = 6.8 Hz, 3H); ¹³C NMR (CDCl₃, 125 MHz): $\delta = 215.8$, 143.2, 138.0, 137.5, 129.5, 129.0, 128.3, 127.6, 127.2, 69.12, 67.0 (br), 48.9 (br), 44.9, 41.0, 29.2, 22.2, 21.4, 20.0, 17.9, 17.8; IR (film): $v_{max} = 3521$ (br), 2970, 1705, 1335, 1157 cm⁻¹; HR-MS (FAB +): m/z = 432.2205, calcd. for C₂₄H₃₃NO₄S (M+H): 432.2203.

(4*R**,5*S**)-5-(*N*-Benzyl-*N*-tosylamino)-4-hydroxy-6methylheptan-2-one (21a, 21b)

Prepared from aldehyde **5** and enol silane **6c** as described for **7a** and **7b** to afford **21a** and **21b** as a colorless oil; yield: 47.3 mg (60%); *dr* 22:78 (*syn:anti*). The following ratios were used: aldehyde 2 equiv., BF₃·OEt₂ 2 equiv., enol silane 1 equiv. The diastereomers were separated by flash chromatography (heptane:EtOAc 8:1 \rightarrow 4:1).

Major isomer **21b.** ¹H NMR (CDCl₃, 400 MHz, 55 °C): $\delta =$ 7.70 (d, J = 8.1 Hz, 2H), 7.46 (d, J = 7.0 Hz, 2H), 7.36–7.24 (m, 5H), 4.64 (d, J = 15.5 Hz, 1H), 4.32 (d, J = 15.5 Hz, 1H), 4.04 (unresolved m, 1H), 3.44 (dd, J = 6.2, 6.2 Hz 1H), 3.09 (br s, 1H), 2.63–2.46 (m, 2H), 2.44 (s, 3H), 2.01 (s, 3H), 1.99–1.87 (m, 1H), 1.04 (d, J = 6.7 Hz, 3H), 0.75 (d, J = 6.8 Hz, 3H); ¹³C NMR (CDCl₃, 100 MHz, 45 °C): $\delta = 209.6$, 143.3, 138.4, 137.6, 129.6, 129.2, 128.5, 127.8, 127.4, 69.5, 67.2 (br), 49.3 (br), 48.0, 30.3, 29.4, 22.3, 21.4, 20.0; IR (film):

 $v_{\text{max}} = 3618$ (br), 2962, 1709, 1334, 1157 cm⁻¹; HR-MS (FAB+): m/z = 404.1890, calcd. for $C_{22}H_{29}NO_4S$ (M+H): 404.1890.

(5*S**,6*S**/5*R**,6*S**)-6-Chloro-5-hydroxy-2,2,7-trimethyloctan-3-one (7a, 7b)

To a solution of Ph_3CBF_4 (657 mg, 1.99 mmol) in CH_2Cl_2 (17 mL) at -60 °C was added **1** (80 mg, 0.66 mmol) and the solution stirred for 15 min followed by addition of **6a** (229 mg, 1.33 mmol). The resultant mixture stirred for 18 h and then quenched by addition of H_2O (17 mL) and allowed to reach room temperature. The aqueous phase was extracted with CH_2Cl_2 (3×10 mL), dried (MgSO₄) and concentrated under reduced pressure. The residue was purified by flash chromatography (pentane:EtOAc 12:1) to afford **7a** and **7b** as a colorless oil; yield: 117 mg (80%); *dr* 84:16 (*syn:anti*). See above for characterization details.

(5*S**,6*S**/5*R**,6*S**)-5-Chloro-4-hydroxy-6-methylheptan-2-one (9a, 9b)

Prepared from aldehyde **1** and enol silane **6c** as described for **7a** and **7b**. The mixture was purified by flash chromatography (pentane:EtOAc 6:1) to afford **9a** and **9b** as colorless oils; yield: 99 mg (83%); dr 37:63 (syn:anti). See above for characterization details.

Mukaiyama Aldol Reaction: Aldehydes 28–37

The experimental procedure for Mukaiyama aldol reaction of aldehyde **28** is representative for all aldehydes **28–37**.

(6*S**,7*R**)-6,7-Bis(benzyloxy)-5-hydroxy-2,2-dimethyl-9-phenylnonan-3-one (38a, 38b)

To a stirred solution of **28** (27.3 mg, 72.9 μ mol) in CH₂Cl₂ (1 mL) was added BF₃·OEt₂ (28 μ L, 219 μ mol) at -60 °C. After 5 min. was added **6a** (32 μ L, 146 μ mol) and the resultant solution was stirred at -60 °C for 18 h. The reaction was quenched by addition of H₂O (5 mL) and allowed to reach room temperature. The aqueous phase was extracted with CH₂Cl₂ (3×7 mL), dried (MgSO₄) and concentrated under reduced pressure to afford **38a** and **38b** as a colorless oil; yield: 34.5 mg (99%); *dr* 86:14 (*syn:anti*).

Major isomer **38b.** ¹H NMR (400 MHz, CDCl₃): δ =7.28 (m, 15H), 4.82 (d, *J*=11.7 Hz, 1 H), 4.69 (d, *J*=8.1 Hz, 1 H), 4.66 (d, *J*=7.9 Hz, 1 H), 4.55 (d, *J*=11.5 Hz, 1 H), 4.12 (ddt, *J*=6.2, 3.5, 2.4 Hz, 1 H), 3.79 (td, *J*=8.0, 3.4 Hz, 1 H), 3.67 (dd, *J*=6.4, 3.4 Hz, 1 H), 3.39 (d, *J*=3.7 Hz, 1 H), 2.93 (dd, *J*=18.1, 2.3 Hz, 1 H), 2.86 (m, 1 H), 2.67 (ddd, *J*=13.8, 10.1, 6.4 Hz, 1 H), 2.57 (dd, *J*=18.2, 9.2 Hz, 1 H), 2.06 (m, 1 H), 1.94 (m, 1 H), 1.08 (s, 9 H); ¹³C NMR (100 MHz, CDCl₃): δ =218.3, 142.4, 138.5, 128.48, 128.44, 128.42, 128.37, 128.1, 128.0, 127.72, 127.68, 125, 81.5, 79.1, 73.7, 71.9, 68.2, 44.4, 39.5, 31.9, 31.7, 26.3; IR (film): v_{max} =3485 (br), 1703, 1454, 1073 cm⁻¹; HR-MS (FAB+): *m*/*z*=475.2838, calcd. for C₃₁H₃₈O₄ (M+H): 475.2848.

(6*S**,7*R**)-6,7-Bis(benzyloxy)-5-hydroxy-2,2-dimethyltridecan-3-one (39b, 39b)

Prepared from aldehyde **29** as described for **38** to afford **39a** and **39b** as a colorless oil; yield: 92 mg (93%); *dr* 84:16 (*syn:anti*).

Major isomer **39b.** ¹H NMR (500 MHz, CDCl₃): δ =7.32 (m, 10 H), 4.79 (d, *J*=11.6 Hz, 1H), 4.67 (d, *J*=11.6 Hz, 1H), 4.62 (d, *J*=11.5 Hz, 1H), 4.55 (d, *J*=11.5 Hz, 1H), 4.13 (ddt, *J*=6.0, 3.6, 2.3 Hz, 1H), 3.72 (m, 1H), 3.62 (dd, *J*=6.2, 3.5 Hz, 1H), 3.43 (d, *J*=3.7 Hz, 1H), 2.92 (dd, *J*=18.1, 2.3 Hz, 1H), 2.58 (dd, *J*=18.2, 9.2 Hz, 1H), 1.69 (m, 1H), 1.59 (m, 1H), 1.48 (m, 1H), 1.30 (m, 7H), 1.07 (s, 9H), 0.88 (t, *J*=6.9 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃): δ =218.4, 138.6, 138.5, 128.36, 128.32, 128.1, 127.8, 127.6, 127.5, 81.7, 79.7, 73.6, 71.9, 68.2, 44.3, 39.4, 31.8, 29.9, 29.4, 26.2, 25.6, 22.6, 14.1; IR (film): v_{max}=3492(br), 1696, 1455, 1089 cm⁻¹; HR-MS (FAB+): m/z=461.3222, calcd. for C₂₉H₄₂O₄ (M+Li): 461.3238.

(6*R**,7*R**)-6,7-Bis(benzyloxy)-5-hydroxy-2,2-dimethyl-9-phenylnonan-3-one (40a, 40b)

Prepared from aldehyde **30** as described for **38** to afford **40a** and **40b** as a colorless oil; yield: 32 mg (90%); *dr* 51:49 (*syn:anti*).

Mixture of isomers. ¹H NMR (400 MHz, CDCl₃): $\delta = 7.26$ $(m, 15 H_{mai}, 15 H_{min}), 4.79 (AB-d, J=11.7 Hz, 1 H_{mai}), 4.72-$ 4.54 (m, $3 H_{mai}$, $4 H_{min}$), 4.28 (m, $1 H_{min}$), 4.18 (qd, J = 5.0, $3.7 \text{ Hz}, 1 \text{H}_{\text{maj}}$, $3.76 \text{ (ddd, } J = 8.1, 6.3, 3.9 \text{ Hz}, 1 \text{H}_{\text{maj}}$), 3.60(m, $2H_{min}$), 3.51 (d, J=3.46 Hz, $1H_{min}$), 3.44 (dd, J=6.3, 3.6 Hz, $1 H_{maj}$), 2.87 (d, J = 5.2 Hz, $1 H_{maj}$), 2.85–2.51 (m, $3 H_{mai}$, $4 H_{min}$), 2.44 (dd, J = 17.9, 3.8 Hz, $1 H_{mai}$), 2.09–1.96 $(m, 1H_{mai}, 2H_{min}), 1.88 (m, 1H_{mai}), 1.07 (s, 9H_{min}), 1.04 (s, s)$ $9 H_{mai}$); ¹³C NMR (125 MHz, CDCl₃): $\delta = 216.8, 216.2, 142.1,$ 141.8, 138.5, 138.1, 138.2, 138.0, 128.46, 128.47, 128.40, 128.38, 128.36, 128.35, 128.2, 128.1, 128.21, 127.9, 127.8, 127.7, 125.3, 125.77, 81.5, 80.6, 79.1 78.5, 74.4, 73.7, 73.0, 72.5, 68.5, 67.4, 44.3, 44.2, 40.5, 39.6, 32.7, 31.9, 31.8, 31.7, 26.22, 26.18; IR (film): $\nu_{max}\!=\!3489$ (br), 1703, 1454, 1070 cm⁻¹; HR-MS (FAB+): m/z = 475.2838, calcd. for C₃₁H₃₈O₄ (M+H): 475.2848.

(6*R**,7*R**)-6,7-Bis(benzyloxy)-5-hydroxy-2,2-dimethyltridecan-3-one (41a, 41b)

Prepared from aldehyde **31** as described for **38** to afford **41a** and **41b** as a colorless oil; yield: 49 mg (92%); *dr* 55:45 (*syn:anti*).

Minor isomer **41a**. ¹H NMR (400 MHz, CDCl₃): δ =7.30 (m, 10H), 4.67 (d, *J*=11.8 Hz, 4H), 4.29 (dq, *J*=6.2, 3.1 Hz, 1H), 3.59 (dt, *J*=6.4, 3.9 Hz, 1H), 3.54 (dd, *J*=5.8, 3.8 Hz, 1H), 3.50 (d, *J*=3.5 Hz, 1H), 2.82 (dd, *J*=17.7, 2.8 Hz, 1H), 2.63 (dd, *J*=17.7, 8.9 Hz, 1H), 1.66 (m, 2H), 1.29 (m, 8H), 1.08 (s, 9H), 0.88 (t, *J*=6.9 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃): δ =217.0, 138.3, 138.2, 128.4, 128.3, 128.2, 127.8, 128.2, 127.7, 80.9, 79.5, 73.8, 72.5, 68.6, 44.3, 39.7, 31.8, 30.2, ,29.4, 26.2, 25.9, 22.6, 14.1.

Major isomer **41b.** ¹H NMR (400 MHz, CDCl₃): δ =7.30 (m, 10H), 4.83 (d, *J*=11.7 Hz, 1H), 4.63 (m, 3H), 4.16 (m, 1H), 3.73 (ddd, *J*=7.8, 6.4, 4.2 Hz, 1H), 3.39 (dd, *J*=6.3, 3.5 Hz, 1H), 2.88 (d, *J*=5.1 Hz, 1H), 2.73 (dd, *J*=17.9, 8.5 Hz, 1H), 2.45 (dd, *J*=17.9, 3.7 Hz, 1H), 1.66 (m, 2H),

© 2011 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim

1.29 (m, 8H), 1.08 (s, 9H), 0.88 (t, J=6.9 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃): δ =216.3, 138.7, 138.43, 128.43, 128.3, 128.0, 127.8, 127.6, 81.9, 80.1, 74.5, 73.1, 67.5, 44.2, 40.6, 31.8, 31.0, 29.5, 26.2, 25.5, 22.6, 14.1; IR (film): v_{max} =348 0(br), 1703, 1455, 1072 cm⁻¹; HR-MS (FAB+): *m*/ *z*=455.3154, calcd. for C₂₉H₄₂O₄ (M+H): 455.3156.

N-Benzyl-*N*-{(1*R**,2*R**)-1-[(*S**)-1-(*tert*-butyl)dimethylsilanyloxy-3-phenylpropyl]-2-hydroxy-5,5dimethyl-4-oxohexyl}-4-methylbenzenesulfonamide (42b)

Prepared from aldehyde **32** as described for **38a** and **38b** to afford **42b** as a colorless oil; yield: 141 mg (92%); dr > 2:98 (*syn:anti*). ¹H NMR (400 MHz, CDCl₃): $\delta = 7.75$ (d, J = 8.0 Hz, 2H), 7.51 (d, J = 6.8 Hz, 2H), 7.37–7.18 (m, 10H), 4.81 (d, J = 15.2 Hz, 1H), 4.40 (d, J = 15.2 Hz, 1H), 4.24 (m, 1H), 4.07 (m, 1H), 3.91 (m, 1H), 3.64 (d, J = 2.3 Hz, 1H), 2.88 (dt, J = 13.0, 4.6 Hz, 1H), 2.69 (m, 1H), 2.61 (dt, J = 13.0, 4.6 Hz, 1H), 1.03 (s, 9H), 0.92 (s, 3H), 0.02 (s, 3H), -0.02 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 215.6$, 143.5, 142.6, 138.0, 137.7, 129.8, 129.0, 128.6, 128.5, 128.3, 127.7, 127.3, 125.6, 72.4, 68.9, 44.0, 41.6, 35.8, 28.8, 26.0, 21.4, 18.1, -4.3, -4.4; IR (film): $v_{max} = 2960$, 1690, 1160 cm⁻¹; HR-MS (FAB+): m/z = 652.3484, calcd. for C₃₇H₃₃NO₅SSi (M+H): 652.3492.

N-Benzyl-*N*-{(1*R**,2*R**)-1-[(*S**)-1-(*tert*-butyl)dimethylsilanyloxy-3-cyclohexyl-ethyl]-2-hydroxy-5,5dimethyl-4-oxohexyl}-4-methylbenzenesulfonamide (43b)

Prepared from aldehyde **33** as described for **38a** and **38b** to afford **43b** as a colorless oil; yield: 29 mg (81%); dr > 2:98 (*syn:anti*). ¹H NMR (500 MHz, d8-PhMe, 90 °C): $\delta = 7.61$ (d, J = 8.2 Hz, 2H), 7.41 (d, J = 7.4 Hz, 2H), 7.13–6.82 (m, 5H), 4.68 (d, J = 15.4 Hz, 1H), 4.50 (m, 1H), 4.34 (d, J = 15.4, 1H), 4.04–3.90 (m, 2H), 3.47 (s, 3H), 2.71 (dd, J = 17.0, 9.6 Hz, 1H), 2.27 (d, J = 17.0 Hz, 1H), 1.99–0.94 (m, 29H), 0.17 (s, 3H), -0.02 (s, 3H); ¹³C NMR (125 MHz, DMSO- d_6): $\delta = 213.8$, 137.9, 134.8, 130.4, 129.1, 128.6, 127.8, 127.6, 75.6, 67.9, 62.7, 43.8, 43.2, 30.1, 27.0, 26.3, 24.5, 21.4, 19.1, -1.7, -4.5; IR (film): $v_{max} = 3450$, 2970, 1690, 1340, 1160 cm⁻¹; HR-MS (FAB+): m/z = 630.3643, calcd. for C₃₅H₅₅NO₅SSi (M+H): 630.3648.

N-Benzyl-*N*-{(1*S**,2*S**/1*S**,2*R**)-1-[(*S**)-1-(*tert*-butyl)dimethylsilanyloxy-3-phenylpropyl]-2-hydroxy-5,5dimethyl-4-oxohexyl}-4-methylbenzenesulfonamide (44a, 44b)

Prepared from aldehyde **34** as described for **38a** and **38b** to afford **44a** and **44b** as a colorless oil; yield: 45 mg (91%); dr 53:47 (*syn:anti*). The diastereomers were separated by flash chromatography (pentane:EtOAc 20:1).

Major isomer **44a**. ¹H NMR (400 MHz, CDCl₃): δ = 7.49– 7.02 (m, 14 H), 4.72 (d, *J* = 16.0 Hz, 1 H), 4.62 (d, *J* = 16.0 Hz, 1 H), 4.30 (m, 1 H), 4.11 (dd, *J* = 8.9, 2.5 Hz, 1 H), 3.94 (dt, *J* = 6.1, 2.5 Hz, 1 H), 2.97 (d, *J* = 4.5 Hz, 1 H), 2.82 (dd, *J* = 18.0, 2.0 Hz, 1 H), 2.57 (m, 3 H), 2.43 (s, 3 H), 1.96 (m, 1 H), 1.62 (m, 1 H), 1.11 (s, 9 H), 0.82 (s, 9 H), 0.08 (s, 3 H), 0.04 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ =216.3, 142.6, 141.5, 138.3, 137.8, 128.8, 128.7, 128.5, 128.3, 128.0, 127.9, 127.0, 125.9, 74.1, 65.3, 64.2, 49.7, 44.3, 41.2, 35.7, 32.3, 26.2, 25.9, 21.4, 18.0, -4.4, -4.5; IR (film): v_{max}=2960, 1700, 1160 cm⁻¹; HR-MS (FAB+): m/z=652.3503, calcd. for C₃₇H₅₃NO₅SSi (M+H): 652.3492.

Minor isomer **44b.** ¹H NMR (400 MHz, CDCl₃): δ =7.43 (m, 2H), 7.32–7.18 (m, 8H), 7.07 (d, *J*=7.0 Hz, 2H), 6.91 (d, *J*=8.1 Hz, 2H), 4.79 (d, *J*=14.5 Hz, 1H), 4.61 (d, *J*= 14.5 Hz, 1H), 4.43 (dt, *J*=6.3, 2.3 Hz, 1H), 4.27 (m, 1H), 3.97 (dd, *J*=10.2, 2.3 Hz, 1H), 3.59 (d, *J*=3.2 Hz, 1H), 2.87 (d, *J*=18.5 Hz, 1H), 2.73–2.51 (m, 3H), 2.24 (s, 3H), 2.22 (m, 2H), 1.10 (s, 9H), 0.87 (s, 9H), 0.14 (s, 3H), 0.05 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ =218.6, 142.8, 141.6, 138.3, 137.3, 129.8, 129.0, 128.4, 128.3, 128.0, 127.5, 127.3, 125, 72.4, 65.1, 63.5, 49.9, 44.3, 40.9, 36.7, 32.7, 26.4, 26.2, 21.4, 18.3, -4.2, -5.2; IR (film): v_{max}=2960, 1690, 1160 cm⁻¹; HR-MS (FAB+): *m*/*z*=674.3324, calcd for C₃₇H₅₃NO₅SSi (M+Na): 674.3311.

N-Benzyl-*N*-{(1*S**,2*S**/1*S**,2*R**)-1-[(*S**)-1-(*tert*-butyl)dimethylsilanyloxy-3-cyclohexylmethyl]-2-hydroxy-5,5-dimethyl-4-oxohexyl}-4-methylbenzenesulfonamide (45a, 45b)

Prepared from aldehyde **35** as described for **38a** and **38b** to afford **45a** and **45b** as a colorless oil; yield: 34 mg (49%); *dr* 56:44 (*syn:anti*). The diastereomers were separated by preparative HPLC (hexane:*i*-PrOH 99:1).

Major isomer **45a**. ¹H NMR (400 MHz, CDCl₃): δ = 7.51– 7.12 (m, 9H), 4.72 (d, *J*=16.2 Hz, 1H), 4.56 (d, *J*=16.2 Hz, 1H), 4.34 (m, 1H), 3.98 (dd, *J*=9.4, 3.0, 1H), 3.75 (t, *J*=3.5, 1H), 3.10 (d, *J*=17.3, 1H), 2.90 (d, *J*=4.6 Hz, 1H), 2.51 (dd, *J*=17.3, 9.0 Hz, 1H), 2.37 (s, 3H), 1.57–0.79 (m, 29H), 0.16 (s, 3H), 0.13 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 216.7, 142.6, 138.7, 137.7, 128.9, 128.7, 128.1, 127.9, 127.1, 79.7, 77.3, 65.2, 49.8, 44.3, 42.1, 39.7, 31.8, 28.6, 26.3, 26.2, 26.09, 26.05, 21.4, 18.5, -3.3, -4.7; IR (film): v_{max}=3490, 1700, 1340, 1100 cm⁻¹; HR-MS (FAB+): *m/z*=630.3651, calcd. for C₃₅H₅₅NO₅SSi (M+H): 630.3648.

Minor isomer **45b.** ¹H NMR (400 MHz, CDCl₃): δ = 7.31– 7.01 (m, 9H), 4.82 (d, *J*=14.5 Hz, 1H), 4.48 (d, *J*=14.5 Hz, 1H), 4.33 (m, 1H), 4.13 (m, 2H), 3.36 (s, 1H), 2.91 (m, 1H), 2.69 (m, 1H), 2.33 (s, 3H) 1.99–0.80 (m, 29H), 0.21 (s, 3H), 0.13 (s, 3H); ¹³C NMR (125 MHz, CDCl₃); δ =218.6, 142.6, 138.5, 136.8, 129.7, 128.9, 127.9, 127.5, 127.3, 109.0, 64.9, 62.1, 50.3, 44.4, 41.2, 39.8, 31.1, 29.7, 29.4, 26.9, 26.4, 26.3, 26.0, 21.3, 18.7, -3.5, -4.5; IR (film): v_{max} =3500, 1690, 1100 cm⁻¹; HR-MS (FAB+): *m*/*z*=630.3648, calcd. for C₃₅H₅₅NO₅SSi (M+H): 630.3648.

(5*S**,6*S**,7*R**)-6-Chloro-5-yloxy-(*tert*-butyl)dimethylsilane-7-hydroxy-2,2-dimethyl-9-phenylnonan-3-one (46a)

Prepared from aldehyde **36** as described for **38** to afford **46a** as a colorless oil; yield: 16 mg (99%); *dr* 95:5 (*syn:anti*).

Major isomer **46a.** ¹H NMR (500 MHz, CDCl₃): δ =7.13 (m, 5H), 4.56 (ddt, *J*=6.3, 2.7, 1.2 Hz, 1H), 4.04 (dd, *J*=11.0, 5.4 Hz, 1H), 3.90 (dd, *J*=5.5. 1.2 Hz, 1H), 3.40 (d, *J*=2.8 Hz, 1H), 2.76 (dd, *J*=6.2, 5.7 Hz, 2H), 2.66 (ddd, *J*=13.5, 11.3, 5.1 Hz, 1H), 2.55 (ddd, *J*=13.5, 11.1, 6.0 Hz, 1H),

1.95 (m, 2H), 1.05 (s, 9H), 0.81 (s, 9H), 0.14 (d, J=20.9 Hz, 6H); ¹³C NMR (125 MHz, CDCl₃): δ =215.3, 141.5, 129.3, 128.4, 128.3, 125.9, 74.8, 65.7, 65.4, 44.3, 41.4, 36.7, 30.3, 26.2, 25.8, 18.0, -4.5, -4.7; IR (film): v_{max}=3436 (br), 1702, 1644, 1255, 1095, 837, 777 cm⁻¹; HR-MS (FAB+): m/z=427.2428, calcd for C₂₃H₃₉ClO₃Si (M+H): 427.2430.

(5*S**,6*S**,7*R**)-6-Chloro-5-yloxy-(*tert*-butyl)dimethylsilane-7-hydroxy-2,2-dimethyl-9phenylnonan-3-one (47a)

Prepared from aldehyde **37** as described for **38** to afford **47a** as a colorless oil; yield: 24 mg (94%); *dr* 91:9 (*syn:anti*).

Major isomer **47a**. ¹H NMR (CDCl₃, 500 MHz): δ =7.25 (m, 5H), 4.41 (m, 1H), 4.01 (dd, *J*=4.7, 2.7 Hz, 1H), 3.14 (d, *J*=4.1 Hz, 1H), 2.85 (m, 2H), 2.67 (m, 2H), 2.14 (s, 1H), 1.91 (m, 1H), 1.16 (s, 9H), 0.93 (s, 9H), 0.12 (d, *J*=2.6 Hz, 6H); ¹³C NMR (CDCl₃, 125 MHz): δ =215.2, 141.5, 128.5, 128.3, 126.0, 74.8, 68.2, 68.1, 44.4, 41.4, 35.7, 31.2, 26.4, 26.2, 25.8, 18.1, -4.1, -4.4; IR (film): v_{max} =3488, 1703, 1255, 1095, 1072, 837, 778 cm⁻¹; HR-MS (FAB+): *m*/*z*=427.2431, calcd for C₂₃H₃₉ClO₃Si (M+H): 427.2430.

Boron Enolate Addition to Aldehyde 1: (4*R*,5*S*/ 4*S*,5*R*)-6-Chloro-5-hydroxy-2,4,7-trimethyloctan-3-one (24a, 24b)

To a stirred solution of 2-methyl-3-pentanone (41 mL, 332 mmol) in Et₂O (0.6 mL) was added (c-Hex)₂BCl (349 mL, 1 M in hexane) and Et₃N (51 mL, 365 mmol) at 0°C. The solution turned white and was stirred for 1 h before it was cooled down to -78 °C and 1 (40 mg, 332 mmol) dissolved in Et₂O (0.4 mL) was added dropwise. The resultant mixture was stirred at -78°C for 2 h, allowed to warm up to 0°C and after 10 min. quenched by sequential addition of phosphate buffer pH7 (1.5 mL), MeOH (1.5 mL) and H₂O₂ (1.5 mL). The mixture was stirred for additional 30 min at room temperature and diluted with buffer (5 mL) and CH₂Cl₂ (5 mL). The aqueous phase was extracted (CH₂Cl₂, 3×5 mL), the combined organic phases were washed (1:1 NaS₂O₃, 20 wt%, aqueous and NaHCO₃, saturated, aqueous), dried (Na₂SO₄) and concentrated to afford 24a and 24b as a colorless oil; yield: 30 mg (50%); dr 13:87 (syn:anti). The diastereomers were separated by flash chromatography (pentane:EtOAc 16:1).

Minor isomer **24a**. ¹H NMR (CDCl₃, 400 MHz): $\delta = 3.67$ (dd, J = 8.6, 1.7 Hz, 1 H), 4.03 (d, J = 7.9, 1 H), 3.06 (m, 1 H), 2.74 (sept, J = 6.9 Hz, 1 H), 2.11 (m, 1 H), 1.08 (m, 9 H), 1.01 (m, 6 H); ¹³C NMR (CDCl₃, 125 MHz): $\delta = 218.1$, 73.1, 71.8, 48.6, 41.1, 32.7, 20.8, 20.1, 18.0, 17.9, 13.9; HRMS (FAB +): m/z = 221.1302, calcd. for C₁₁H₂₁ClO₂ (M+H): 221.1303.

Major isomer **24b.** ¹H NMR (CDCl₃, 500 MHz): $\delta = 3.99$ (s, 1H), 3.64 (dd, J = 10.1, 2.3 Hz, 1H), 3.52 (d, J = 10.2 Hz, 1H), 3.46 (dq, J = 7.4, 2.8 Hz, 1H), 2.77 (sept, J = 6.9 Hz, 1H), 2.54 (dsept, J = 6.7, 2.32 Hz, 1H), 1.32 (d, J = 7.35 Hz, 3H), 1.14 (d, J = 7.0 Hz, 3H), 1.10 (d, J = 6.82 Hz, 3H), 1.01 (d, J = 6.85 Hz, 3H), 0.92 (d, J = 6.58 Hz, 3H); ¹³C NMR (CDCl₃, 125 MHz): $\delta = 223.1$, 76.3, 70.8, 43.3, 40.9, 28.8, 20.9, 18.1, 17.6, 15.7, 14.5; IR (film): $v_{max} = 3413$ (br), 1641, 1065, 1025, 742 cm⁻¹; HR-MS (FAB+): m/z = 221.1302, calcd for C₁₁H₂₁ClO₂ (M+H): 221.1303.

(4*R**,5*R**,6*S**)-6-Chloro-5-hydroxy-2,4,7-trimethyloctan-3-one (25b)

To 2-methyl-3-pentanone (41 mL, 332 mmol) in Et₂O (0.6 mL) at 0°C was added 9-BBNOTf (730 mL, 0.5 M in hexane) and DIPEA (69 mL, 398 mmol). The solution turned yellow and was allowed to reach room temperature and stirred for 1 h before it was cooled down to -78°C and 1 (40 mg, 332 mmol) dissolved in Et_2O (0.7 mL) was added dropwise. The resultant mixture was stirred at -78°C for 2 h, allowed to warm up to 0°C and after 10 min. quenched by sequential addition of phosphate buffer pH7 (1.5 mL), MeOH (1.5 mL) and H_2O_2 (1.5 mL). The mixture was stirred for additional 30 min at room temperature, then diluted with buffer (5 mL) and CH_2Cl_2 (5 mL). The aqueous phase was extracted (CH₂Cl₂, 3×5 mL), the combined organic phases were washed (1:1 NaS₂O₃, 20 wt%, aqueous and NaHCO₃ saturated, aqueous), dried (Na₂SO₄) and concentrated. The residue was purified by flash chromatography (pentane:EtOAc 16:1) to afford 25b as a colorless oil; yield: 61 mg (99%); dr 94:6 (syn:anti).

Major isomer **25b.** ¹H NMR (CDCl₃, 500 MHz): δ =3.93 (td, J=10.1, 1.7, 1.7 Hz, 1H), 3.77 (dd, J=10.1, 2.2 Hz, 1H), 3.61 (d, J=1.9 Hz, 1H), 3.35 (dq, J=7.3, 7.3, 7.3, 1.5 Hz, 1H), 2.82 (sept., J=6.9, 6.9, 6.9, 6.9, 6.9, 6.9 Hz, 1H), 2.46 (dtd, J=13.4, 6.7, 6.7, 2.2 Hz, 1H), 1.38–1.10 (m, 9H), 1.04 (d, J=6.8 Hz, 3H), 0.94 (d, J=6.6 Hz, 3H); ¹³C NMR (CDCl₃, 125 MHz): δ =221.3, 71.1, 67.8, 43.9, 40.0, 28.1, 20.9, 18.7, 17.8, 14.5, 8.6; IR (film): v_{max} =3451 (br), 1681, 1090, 1017, 735 cm⁻¹; HR-MS (FAB+): m/z=221.1301, calcd for C₁₁H₂₁ClO₂ (M+H): 221.1303.

Sakurai Allylation Reaction of Aldehydes 28–37

The experimental procedure for Sakurai allylation of aldehyde **28** is representative for all aldehydes **28–37**.

(5*S**,6*R**)-5,6-Bis(benzyloxy)-8-phenyloct-1-en-4-ol (49a, 49b)

To a stirred solution of **28** (22.2 mg, 59.3 µmol) in CH₂Cl₂ (1 mL) was added BF₃·OEt₂ (23 µL, 178 µmol) at -60 °C. After 5 min. was added allyl trimethylsilane (19 µL, 119 µmol) and the resultant solution was stirred at -60 °C for 18 h. The reaction was quenched by addition of H₂O (5 mL) and allowed to reach room temperature. The aqueous phase was extracted with CH₂Cl₂ (3×2.5 mL), dried (MgSO₄) and concentrated under reduced pressure. Flash chromatography (pentane:EtOAc 8:1) of the residue gave **49a** and **49b** as colorless oil; yield: 23.4 mg (95%); *dr* 87:13 (*syn:anti*).

Major isomer **49b.** ¹H NMR (500 MHz, CDCl₃): δ =7.27 (m, 15H), 5.82 (m, 1H), 5.13 (m, 2H), 4.77 (d, *J*=11.4 Hz, 1H), 4.65 (dd, *J*=11.4, 8.5 Hz, 2H), 4.56 (d, *J*=11.5 Hz, 1H), 3.79 (m, 2H), 3.57 (dd, *J*=6.6, 3.6 Hz, 1H), 2.86 (m, 1H), 2.67 (m, 1H), 2.52 (m, 1H), 2.24 (m, 2H), 2.10 (ttd, *J*=11.6, 9.0, 4.5 Hz, 1H), 1.99 (m, 1H); ¹³C NMR (125 MHz, CDCl₃): δ =142.2, 138.4, 138.3, 135.0, 128.43, 128.41, 128.36, 128.3, 127.95, 127.89, 127.70, 127.67, 125.7, 118.1, 81.9, 79.5, 73.63, 72.0, 71.0, 38.0, 32.2, 31.8; IR (film): v_{max}=3428 (br), 1640, 1454, 1095, 1071, 916 cm⁻¹; HR-MS (FAB+): *m*/*z*=417.2423, calcd. for C₂₈H₃₂O₃ (M+H): 417.2424.

(5*R**,6*S**)-5,6-Bis(benzyloxy)dodec-1-en-4-ol (50a, 50b)

Prepared from aldehyde **29** as described for **49** to afford **50a** and **50b** as a colorless oil; yield: 118 mg (93%); *dr* 84:16 (*syn:anti*).

Major isomer **50b**: ¹H NMR (500 MHz, CDCl₃): δ =7.45–7.29 (m, 10H), 5.95 (m, 1H), 5.23–5.13 (m, 2H), 4.78 (d, *J*=11.4 Hz, 1H), 4.70–4.54 (m, 3H), 3.85 (d, *J*=8.2 Hz, 1H), 3.80–3.73 (m, 1H), 3.54 (dd, *J*=6.6, 3.8 Hz, 1H), 2.65–2.55 (m, 1H), 2.38 (d, *J*=7.9 Hz, 1H), 2.28 (dd, *J*=14.2, 8.3 Hz, 1H), 1.82–1.69 (m, 2H), 1.58–1.46 (m, 1H), 1.44–1.25 (m, 7H), 0.93 (t, *J*=6.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ =138.4, 135.2, 127.92, 127.88, 127.7, 127.6, 118.0, 82.2, 80.4, 73.6, 72.1, 71.3, 38.0, 31.8, 30.5, 29.5, 25.5, 22.6, 14.1; IR (film): v_{max}=3473 (br), 1640, 1455, 1069, 914 cm⁻¹; HR-MS (FAB+): *m*/*z*=397.2742, calcd. for C₂₆H₃₆O₃ (M+H): 397.2737.

(5*R**,6*R**)-5,6-Bis(benzyloxy)-8-phenyloct-1-en-4-ol (51a, 52b)

Prepared from aldehyde **30** as described for **49** to afford **51a** and **51b** as a colorless oil; yield: 5 mg (83%); *dr* 79:21 (*syn:-anti*).

Mixture of isomers. ¹H NMR (400 MHz, CDCl₃): $\delta = 7.32$ -7.09 (m, $15 H_{maj}$, $15 H_{min}$), 5.89 (dddd, J = 23.1, 11.1, 7.7, $6.4 \text{ Hz}, 1 \text{ H}_{\text{min}}$), $5.78 \text{ (tdd, } J = 17.3, 10.3, 7.1 \text{ Hz}, 1 \text{ H}_{\text{mai}}$), 5.12 Hz $(m, 2H_{min}), 5.05 (m, 2H_{mai}), 4.74 (AB-d, J=11.2 Hz, 1H_{mai}),$ 4.64–4.43 (m, $3H_{maj}$, $4H_{min}$), 3.92 (ddd, J=11.1, 7.7, 3.5 Hz, $1 H_{min}$), 3.77 (ddd, $J = 13.6, 6.7, 3.2 Hz, 1 H_{maj}$), 3.69–3.61 (m, $1 H_{maj}$, $1 H_{min}$), 3.51-3.42 (m, $1 H_{maj}$, $2 H_{min}$), 2.84-2.73 (m, $1\,H_{\text{maj}},\,1\,H_{\text{min}}),\,2.59\,\,(\text{m},\,1\,H_{\text{maj}},\,1\,H_{\text{min}}),\,2.67\text{--}2.52\,\,(\text{m},\,1\,H_{\text{maj}},\,1\,H_{\text{maj}}),\,1\,H_{\text{maj}},\,1\,H_{\text{maj}},\,1\,H_{\text{maj}},\,1\,H_{\text{maj}},\,1\,H_{\text{maj}}),\,1\,H_{\text{maj}},\,1\,H$ $1 H_{min}$), 2.44 (dddd, J = 14.3, 6.3, 3.6, 1.6 Hz, $1 H_{min}$), 2.30 (dd, $J = 13.6, 6.9 \text{ Hz}, 2 \text{ H}_{\text{mai}}), 2.37 - 2.17 \text{ (m, } 2 \text{ H}_{\text{min}}), 2.11 - 1.85 \text{ (m, }$ $2H_{maj}, 2H_{min}$); ¹³C NMR (125 MHz, CDCl₃): $\delta = 142.0, 141.7,$ 138.4, 138.1, 137.9, 137.5, 135.1, 134.8, 128.51, 128.46, 128.49, 128.44, 128.41, 128.38, 128.33, 128.1, 128.0, 127.9, 127.8, 127.7, 125.9, 125, 117.5, 117.2, 81.0, 78.8, 78.6, 78.4, 74.4, 73.0, 72.9, 72.4, 70.7, 70.2, 39.3, 38.1, 32.5, 31.95, 31.86, 31.0; IR (film): $v_{max} = 3452$ (br), 1640, 1454, 1067, 915 cm⁻¹; HR-MS (FAB+): m/z = 417.2424, calcd. for $C_{28}H_{32}O_3$ (M+H): 417.2430.

(5*R**,6*R**)-5,6-Bis(benzyloxy)dodec-1-en-4-ol (52a, 52b)

Prepared from aldehyde **31** as described for **49** to afford **52a** and **52b** as a colorless oil; yield: 122 mg (87%); *dr* 67:33 (*syn:anti*).

Mixture of isomers. ¹H NMR (400 MHz, CDCl₃): δ = 7.38– 7.22 (m, 10H_{mai}, 10H_{min}), 5.95–5.86 (m, 1H_{min}), 5.85–5.76 (m, 1H_{mai}), 5.14–5.03 (m, 2H_{mai}, 2H_{min}), 4.81 (AB-d, *J*=11.3, 1H_{mai}), 4.67–4.51 (m, 3H_{mai}, 4H_{min}), 3.92 (m, 1H_{min}), 3.75 (m, 1H_{mai}), 3.63 (m, 1H_{mai}, 1H_{min}), 3.43 (dd, *J*=7.3, 3.9 Hz, 1H_{min}), 3.40 (dd, *J*=6.0, 3.2 Hz, 1H_{mai}), 3.30 (d, *J*=3.4 Hz, 1H_{min}), 2.44 (m, 1H_{min}), 2.35–2.20 (m, 2H_{mai}, 2H_{min}), 1.75–1.49 (m, 2H_{mai}, 1H_{min}), 1.47–1.36 (m, 1H_{mai}, 1H_{min}), 1.35–1.16 (m, 7H_{mai}, 7H_{min}), 0.88 (m, 3H_{mai}, 3H_{min}); ¹³C NMR (100 MHz, CDCl₃): δ =138.6, 138.3, 135.2, 134.9, 128.44, 128.42, 128.3, 128.2, 128.02, 128.00, 127.98, 127.9, 127.8, 127.6, 117.4, 81.6, 79.9, 79.5, 79.1, 74.6, 73.2, 72.9, 72.4, 70.6, 70.5, 39.2, 38.2, 31.8, 31.7, 30.8, 29.4, 29.3, 26.0, 25.6, 22.6, 14.1; IR (film): $v_{max} = 3451$ (br), 1640, 1455, 1069, 915 cm⁻¹; HR-MS (FAB+): m/z = 397.2737, calcd. for C₂₆H₃₆O₃ (M+H): 397.2737.

(3*R**,4*S**,5*S**)-4-*N*-Benzyl-*N*-tosylamino-1-phenyloct-7-ene-3-yloxy-(*tert*-butyl)dimethylsilane-5-ol (53a, 53b)

Prepared from aldehyde **32** as described for **49** to afford **53a** and **53b** as a colorless oil; yield: 37 mg (67%); *dr* 87:13 (*syn:anti*).

Major isomer **53b.** ¹H NMR (500 MHz, CDCl₃): δ =7.70 (d, J=8.2, 2H), 7.38 (d, J=7.3, 2H), 7.24 (m, 10H), 5.61 (tdd, J=17.0, 10.1, 6.9 Hz, 1H), 5.02 (dd, J=10.3, 1.1 Hz, 1H), 4.93 (dd, J=17.1, 1.4 Hz, 1H), 4.73 (d, J=15.6 Hz, 1H), 4.39 (d, J=15.6 Hz, 1H), 4.01 (br s, 1H), 3.89 (br s, 1H), 3.68 (br s, 1H), 3.09 (br s, 1H), 2.75 (dt, J=12.8, 4.6, 1H), 2.56 (dt, J=12.9, 4.1 Hz, 1H), 2.43 (s, 3H), 2.10 (m, 2H), 1.93 (m, 1H), 1.63 (m, 1H), 0.88 (s, 9H), -0.00 (s, 3H), -0.01 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ =143.6, 142.1, 137.8, 135.1, 129.7, 128.5, 128.5, 128.3, 127.6, 127.4, 125.7, 117.0, 73.3, 72.6, 40.1, 36.0, 28.8, 25.9, 21.4, 18.0, -3.8, -4.6; IR (film): v_{max} =3478 (br), 1341, 1160, 836, 778 cm⁻¹; HR-MS (FAB+): m/z=616.2887, calcd. for C₃₄H₄₇NO₄SSi (M+Na): 616.2893.

(3*R**,4*S**,5*S**)-4-Chloro-1-phenyloct-7-ene-3-yloxy-[(*tert*-butyl)dimethylsilane]-5-ol (55a, 55b)

Prepared from aldehyde **36** as described for **49** to afford **55a** and **55b** as a colorless oil: yield: 12 mg (88%); *dr* 40:60 (*syn:anti*).

Mixture of isomers. ¹H NMR (500 MHz, CDCl₃): δ =7.25 (m, 1H), 5.88 (dddd, J=16.8, 10.3, 7.9, 6.3 Hz, 1H_{min}), 5.78 (m, 1H_{maj}), 5.22–5.12 (m, 2H_{maj}, 2H_{min}), 4.17–4.10 (m, 2H_{maj}, 1H_{min}), 3.97–3.91 (m, 2H_{maj}, 1H_{min}), 2.85 (d, J=5.0 Hz, 1H_{maj}), 2.76 (ddd, J=13.4, 11.6, 5.5 Hz, 1H_{min}), 2.66 (m, 2H_{maj}), 2.58 (m, 1H_{min}), 2.49–2.40 (m, 1H_{maj}, 1H_{min}), 2.35–2.27 (m, 1H_{maj}, 1H_{min}), 0.94 (s, 9H_{min}), 0.93 (s, 9H_{maj}), 0.16–0.12 (m, 6H_{maj}, 1H_{min}); ¹³C NMR (125 MHz, CDCl₃): δ =141.8, 141.5, 133.9, 133.8, 129.3, 128.5, 128.4, 128.3, 128.2, 126.0, 125.9, 118.6, 118.2, 74.5, 74.0, 71.5, 68.9, 66.8, 65.7, 39.3, 37.7, 36.5, 35.9, 30.6, 30.4, 25.8, 18.1, 18.0, -4.2, -4.4, -4.5, -4.7; IR (film): v_{max} =3449 (br), 1645, 1457, 1257, 1083, 919, 837, 777 cm⁻¹; HR-MS (FAB+): m/z=369.2013, calcd. for C₂₀H₃₃ClO₂Si (M+H): 369.2011.

(3*R**,4*S**,5*S**)-4-Chloro-1-phenyloct-7-ene-3-yloxy-[(*tert*-butyl)dimethylsilane]-5-ol (56a, 56b)

Prepared from aldehyde **37** as described for **49** to afford **56a** and **56b** as a colorless oil: yield: 21 mg (95%); *dr* 59:41 (*syn:anti*).

Mixture of isomers. ¹H NMR (CDCl₃, 500 MHz): $\delta = 7.23$ -7.16 (m, 5H_{maj}, 5H_{min}), 5.90 (dddd, J = 16.6, 10.3, 8.1, 6.2 Hz, 1H_{maj}), 5.79 (tdd, J = 17.2, 10.2, 7.1 Hz, 1H_{min}), 5.21–5.17 (m, 2H_{maj}, 2H_{min}), 4.15 (ddd, J = 7.7, 4.5, 3.0 Hz, 1H_{maj}), 4.03– 3.91 (m, 1H_{maj}, 3H_{min}), 3.78 (dd, J = 9.2, 2.9 Hz, 1H_{maj}), 3.27 (d, J = 2.6 Hz, 1H_{min}), 2.76 (ddd, J = 13.5, 11.4, 5.3 Hz, 1H_{maj}), 2.70–2.55 (m, 2H_{maj}, 2H_{min}), 2.48 (d, J = 5.3 Hz, 1H_{min}), 2.40–2.27 (m, 1H_{maj}, 1H_{min}), 0.92 (s, 9H_{min}), 0.14 (d, J=6.9 Hz, 6H_{maj}), 0.11 (d, J=4.9 Hz, 6H_{min}); ¹³C NMR (CDCl₃, 125 MHz): δ =141.4, 133.8, 133.7, 128.5, 128.3, 126.0, 118.5, 118.4, 74.5, 74.2, 71.3, 70.8, 68.0, 63.5, 39.5, 38.8, 35.5, 34.1, 32.4, 31.5, 25.82, 25.79, 18.1, 18.0, -4.0, -4.4, -4.5; IR (film): v_{max} =3471 (br), 1602, 1462, 1256, 1090, 997, 837, 777 cm⁻¹; HR-MS (FAB+): m/z=369.2009, calcd. for C₂₀H₃₃ClO₂Si (M+H): 369.2011.

Acknowledgements

This work was financially supported by the Swedish Research Council, the Knut and Alice Wallenberg foundation and the Estonian Science Foundation (Grant No. 7808). We wish to thank P. Villo for her contribution.

References

- a) Comprehensive Organic Synthesis, (Eds.:B. M. Trost, I. Fleming), Pergamon, New York, **1991**, Vol. 2;
 b) Houben-Weyl: Methods of Organic Chemistry, (Eds.:G. Helmchen, R. W. Hoffmann, J. Mulzer, E. Schaumann), Thieme, Stuttgart, **1995**, Vol. E 21b, Chapter 1.3; c) C. H. Heathcock, in: Asymmetric Synthesis, (Ed.: J. D. Morrison), Academic, Orlando, **1984**; Vol. 3, p 111–212; d) D. A. Evans, J. V. Nelson, T. R. Taber. Top. Stereochem. **1982**, 13, 1–115; e) T. Mukaiyama, Org. React. **1982**, 28, 203–331.
- [2] a) R. Mahrwald, B. Schetter, Angew. Chem. 2006, 118, 7668–7687; Angew. Chem. Int. Ed. 2006, 45, 7506–7525;
 b) T. Mukaiyama, I. Shiina, H. Iwadare, M. Saitoh, T. Nishimura, N. Ohkawa, H. Sakoh, K. Nishimura, Y. Tani, M. Hasegawa, K. Yamada, K. Saitoh, Chem. Eur. J. 1999, 5, 121–161.
- [3] a) A. Mengel, O. Reiser, *Chem. Rev.* 1999, 99, 1191–1223; b) E. M. Carreira, in: *Comprehensive Asymmetric Catalasis*, (Eds.: E. N. Jacobsen, A. Pflatz, H. Yamamoto), Springer-Verlag, Heidelberg, 1999, Vol. 3, chap. 29; c) M. Swamura, Y. Ito, in: *Catalytic Asymmetric Synthesis*, (eds.: I. Ojima), Wiley-VCH, Weinhem, 2nd edn, 2000, chap 8B1; d) E. M. Carreira, A. Fettes, C. Marti, *Org. React.* 2006, 67, 1–216.
- [4] a) M. Chérest, H. Felkin, N. Prudent, *Tetrahedron Lett.* 1968, 2199–2204; b) N. T. Anh, O. Eisenstein, *Nouv. J. Chim. Zeitschrift wurde erst 1977 geründet!* 1976, *1*, 61–70; c) N. T. Anh, *Top. Curr. Chem.* 1980, 88, 145–162. For computational studies, see: d) Y.-D. Wu, K. N. Houk, *J. Am. Chem. Soc.* 1987, *109*, 908–910; e) K. N. Houk, M. N. Paddon-Row, N. G. Rondan, Y.-D. Wu, F. K. Brown, D. C. Spellmeyer, J. T Metz, R. J. Loncharich, *Science* 1986, *231*, 1108–1117; f) S. S. Wong, M. N. Paddon-Row, *Aust. J. Chem.* 1991, *44*, 765–770; g) G. Frenking, K. F. Köhler, M. T. Reetz, *Tetrahedron* 1991, ##47##43, 9005–9018.
- [5] See, for example: K. Nakai, M. Kaneko, T.-P. Loh, M. Terada, T. Nakai, *Tetrahedron Lett.* **1990**, *31*, 3909– 3912.
- [6] a) D. A. Evans, S. J. Siska, V. J. Cee, Angew. Chem.
 2003, 115, 1803–1807; Angew. Chem. Int. Ed. 2003, 42, 1761–1765. Similar observations have also been made

by other groups. See, for example: b) S. Diaz-Oltra, J. Murga, E. Falomir, M. Carda, G. Peris, J. A. Marco, *J. Org. Chem.* **2005**, *70*, 8130–8139.

- [7] J. W. Cornforth, R. H. Cornforth, K. K. Mathew, J. Chem. Soc. 1959, 112–127.
- [8] V. J. Cee, C. J. Cramer, D. A. Evans, J. Am. Chem. Soc. 2006, 128, 2920–2930.
- [9] a) D. A. Evans, J. L. Duffy, M. J. Dart, *Tetrahedron Lett.* 1994, 35, 8537–8540; b) D. A. Evans, M. J. Dart, J. L. Duffy, M. G. Yang, *J. Am. Chem. Soc.* 1996, 118, 4322–4343; c) M. T. Reetz, K. Kessler, A. Jung, *Tetrahedron Lett.* 1984. 25, 729–732.
- [10] D. A. Evans, V. J. Cee, S. J. Siska, J. Am. Chem. Soc. 2006, 128, 9433–9441.
- [11] For discussions of the role of syn-pentane interactions in aldol reactions, see: a) W. R. Roush, J. Org. Chem.
 1991, 56, 4151–4157; b) D. V. Patel, F. VanMiddlesworth, J. Donaubauer, P. Gannett, C. J. Sib, J. Am. Chem. Soc. 1986, 108, 4603–4614.
- [12] T. Borg, J. Danielsson, P. Somfai, *Chem. Commun.* 2010, 46, 1281–1283.
- [13] P. Restorp, P. Somfai, Org. Lett. 2005, 7, 893-895.
- [14] For the synthesis of aldehydes 1, 2, 4, 5 and 28–37 see Supporting Information.
- [15] S. Díaz-Oltra, M. Carda, J. Murga, E. Falomir, J. A. Marco, *Chem. Eur. J.* **2008**, *14*, 9240–9254.
- [16] H. C. Brown, K. Ganesan, R. K. Dhar, J. Org. Chem. 1993, 58, 147–153.
- [17] a) S. E. Denmark, W. Lee, J. Org. Chem. 1994, 59, 707–709; b) S. Murata, M. Suzuki, R. Noyori, J. Am. Chem. Soc. 1980, 102, 3248–3249; c) Y. Yamamoto, H. Yatagai, Y. Naruta, K. Maruyama, J. Am. Chem. Soc. 1980, 102, 7107–7109.
- [18] a) A. G. Myers, K. L. Widdowson, J. Am. Chem. Soc.
 1990, 112, 9672–9674; b) A. G. Myers, K. L. Widdowson, P. J. Kukkola, J. Am. Chem. Soc. 1992, 114, 2765–2767.
- [19] For steric and/or electronic reasons all other synclinal structures has been excluded. For a discussion, see ref.^[8b], footnote 31.
- [20] The aldehyde rotamer having the α-chloro substituent perpendicular to the C=O moiety (anti-PFA TS) is judged less likely since it would result in a destabilizing steric interaction between R and one substituent on the enol silane (R' or OTMS).
- [21] For 2-chloropropanal the corresponding conformation having a 30° angle between the C=O and C-Cl bonds is about 1.9 kcalmol⁻¹ higher in energy than the most stable conformer. Notable is that this energy is dramatically reduced when the angle is decreased. See ref.^[7]
- [22] C. H. Heathcock, S. H. Davidsen, K. T. Hug, L. A. Flippin, J. Org. Chem. 1986, 51, 3027–3037.
- [23] C. H. Heathcock, L. Flippin, J. Am. Chem. Soc. 1983, 105, 1667–1668.
- [24] T. Mukaiyama, S. Kobayashi, M. Murakami, *Chem. Lett.* **1985**, *14*, 447–450.
- [25] For an example where a TS structure similar to J has been invoked to rationalize the stereochemical outcome in the addition to an α-silyloxy aldehyde, see:
 A. B. Smith III, S. M. Condon, J. A. McCauley, J. L. Leazer Jr, J. W. Leahy, R. E. Maleczka Jr, J. Am. Chem. Soc. 1997, 119, 947–961.

- [26] C. Alvarez-Ibarra, O. Arjona, R. Pérez-Ossorio, A. Pérez-Rubalcaba, M. L. Quiroga, M. J. Santesmases, J. Chem. Soc. Perkin Trans. 2 1983, 1645–1648. For more examples on diminished selectivities with smaller nucleophiles, see ref.^[4]
- [27] Theoretical studies suggest that α -amino-substituted aldehydes react through PFA TS structures in the boron aldol reaction. See ref.^[7]
- [28] For determination of the relative stereochemistry, see Supporting Information.
- [29] This trend has previously been observed in the additions of small nucleophiles to α,β -bisalkoxy aldehydes, see ref.^[9]